



www.blackrock.com.au/ishares or 1300 474 273

30 September 2019

Market Announcements Office ASX Limited

ANNOUNCEMENT – ANNUAL FINANCIAL REPORT 30 JUNE 2019

BlackRock Investment Management (Australia) Limited (**BIMAL**) is the Responsible Entity for the below listed iShares® exchange traded funds (**Funds**) which are quoted on the ASX.

BIMAL announces the Annual Financial Report for the Funds, for the period ending 30 June 2019.

| ASX Code | Fund |
|----------|-------------------------------------|
| IEU | iShares Europe ETF |
| 100 | iShares Global 100 ETF |
| IXI | iShares Global Consumer Staples ETF |
| IXJ | iShares Global Healthcare ETF |
| IVE | iShares MSCI EAFE ETF |
| IEM | iShares MSCI Emerging Markets ETF |

Important Notice

Issued by BlackRock Investment Management (Australia) Limited ABN 13 006 165 975 AFSL 230523 (**BIMAL**). BIMAL is the responsible entity and issuer of units in the Fund. BIMAL its officers, employees and agents believe that the estimates in this document and the sources on which the estimates are based (which may be sourced from third parties) are correct as at the date of publication. While every care has been taken in the preparation of this document, no warranty of accuracy or reliability is given and no responsibility for this information is accepted by BIMAL, its officers, employees or agents. Except where contrary to law, BIMAL excludes all liability for this information.

Neither the performance nor the repayment of capital or any income of an iShares ETF is guaranteed by any BlackRock entity. Past performance is not a reliable indicator of future performance.

Before investing in an iShares ETF, you should carefully consider whether such products are appropriate for you, read the applicable prospectus or product disclosure statement (PDS) available at www.blackrock.com.au and consult an investment adviser.

An iShares ETF is not sponsored, endorsed, issued, sold or promoted by the provider of the index which a particular fund seeks to track. No index provider makes any representation regarding the advisability of investing in the iShares ETFs. Further information on the index providers can be found on BIMAL's website terms and conditions at www.blackrock.com.au.

For more information about iShares ETFs go to www.blackrock.com.au/ishares or call 1300 474 273.

© 2019 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS, iSHARES and the stylized i logo are registered and unregistered trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners.

** FND **

INTERNATIONAL 2 FUNDS

iShares Europe ETF

ARSN 625 113 528

iShares Global 100 ETF

ARSN 625 113 911

iShares Global Consumer Staples ETF

ARSN 625 114 552

iShares Global Healthcare ETF

ARSN 625 114 347

iShares MSCI EAFE ETF

ARSN 625 116 887

iShares MSCI Emerging Markets ETF

ARSN 625 115 844

Annual Financial Report

30 June 2019

BlackRock Investment Management (Australia) Limited 13 006 165 975 Australian Financial Services Licence No 230523



International 2 Funds

Financial Report - For the period 29 March 2018 to 30 June 2019

Contents

| | Page |
|--|------|
| Directors' Report | 1 |
| Auditor's Independence Declaration | 7 |
| Statements of Profit or Loss and Other Comprehensive Income | 8 |
| Statements of Financial Position | 10 |
| Statements of Changes in Equity | 11 |
| Statements of Cash Flows | 12 |
| Notes to the Financial Statements | 14 |
| Directors' Declaration | 51 |
| Independent Auditor's Report to the Unitholders of International 2 Funds | 52 |

Directors' Report

The directors of BlackRock Investment Management (Australia) Limited (ABN 13 006 165 975) (the "Responsible Entity"), the Responsible Entity of International 2 Funds (the "Funds"), present their annual report together with the financial statements of the Funds, for the period ended 30 June 2019 and the auditor's report thereon. The International 2 Funds comprise of iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF and iShares MSCI Emerging Markets ETF.

Fund Objectives

iShares Europe ETF

The Fund seeks to track the investment results of an index composed of European equities.

iShares Global 100 ETF

The Fund seeks to track the investment results of an index composed of 100 large capitalisation global equities.

iShares Global Consumer Staples ETF

The Fund seeks to track the investment results of an index composed of global equities in the consumer staples sector.

iShares Global Healthcare ETF

The Fund seeks to track the investment results of an index composed of global equities in the healthcare sector.

iShares MSCI EAFE ETF

The Fund seeks to track the investment results of an index composed of large- and mid-capitalisation developed market equities, excluding the U.S. and Canada.

iShares MSCI Emerging Markets ETF

The Fund seeks to track the investment results of an index composed of large- and mid-capitalisation emerging market equities.

Principal Activities

The Funds invest in accordance with the provisions of the Funds' Constitutions.

The Funds were registered on 29 March 2018. The Funds iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF and iShares MSCI Emerging Markets ETF commenced their operations on 14 September 2018, 14 September 2018, 14 September 2018, 14 September 2018, 12 October 2018 and 12 October 2018 respectively.

The Funds are currently listed on the Australian Securities Exchange (ASX). The admission dates of the Australian domiciled ETF and suspension of CDI ETF of iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF and iShares MSCI Emerging Markets ETF were 19 September 2018, 19

The Funds did not have any employees during the period 29 March 2018 to 30 June 2019.

There were no significant changes in the nature of the Funds' activities during the period 29 March 2018 to 30 June 2019.

Directors

The following persons held office as directors of the Responsible Entity during the period or since the end of the period and up to the date of this report:

| Director | Date appointed | Date resigned |
|-------------|----------------------------|---------------------|
| M S McCorry | Appointed 2 December 2009 | |
| A Telfer | Appointed 12 December 2013 | |
| S Flatman | Appointed 28 January 2015 | |
| J Collins | Appointed 29 July 2015 | |
| D Rohe | Appointed 27 July 2016 | Resigned 6 May 2019 |

Review and Results of Operations

During the period, the Funds continued to invest funds in accordance with target asset allocations as set out in the governing documents of the Funds and in accordance with the provisions of the Funds' Constitutions.

Results

The performance of the Funds, as represented by the results of their operations, were as follows:

| iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|--|---|
| For the period 29 March 2018 to | For the period 29 March 2018 to | For the period 29 March 2018 to 30 June 2019 |
| \$'000 | \$'000 | \$'000 |
| 14,893 | 84,771 | 16,293 |
| 4,012 | 11,697 | 1,273 |
| iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| For the period 29 March 2018 to 30 June 2019 \$'000 | For the period 29 March 2018 to 30 June 2019 \$'000 | For the period 29 March 2018 to 30 June 2019 \$'000 |
| 22,699 | 26,115 | 69,318 |
| 5,059 | 2,768 | 7,294 |
| | FTF For the period 29 March 2018 to 30 June 2019 \$'000 14,893 4,012 iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 \$'000 22,699 | ETF 100 ETF For the period 29 March 2018 to 30 June 2019 \$'000 \$'000 iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 \$'000 \$'000 22,699 \$'000 |

Returns

The table below demonstrates the performance of the Funds as represented by the total return.

| | Returns* |
|---|--------------------|
| | For the period |
| | 29 March 2018 |
| | to 30 June 2019 |
| | % |
| iShares Europe ETF returns | 3.84 |
| • | |
| iShares Global 100 ETF returns | 5.54 |
| iShares Global Consumer Staples ETF returns | 9.24 |
| iShares Global Healthcare ETF returns | 3.76 |
| iShares MSCI EAFE ETF returns | 7.14 |
| iShares MSCI Emerging Markets ETF returns | 10.12 |

^{*} Returns (after fees) are calculated on the assumption that all distributions are reinvested in the Funds, and include the effect of compounding.

Reconciliation of Net Asset Value for Unit Pricing Purposes to Financial Reporting Purposes

The key differences between net assets for unit pricing purposes and net assets attributed to unitholders as reported in the financial statements prepared under Australian Accounting Standards have been outlined below:

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|----------------------------------|---------------------------|---|
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Net assets for Unit Pricing Purposes Timing differences Other | 704,722 | 1,619,556 | 184,053 |
| Other | <u>-</u> | (1) | <u>-</u> |
| Net assets attributable to unitholders as at 30 June | 704,722 | 1,619,555 | 184,053 |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Net assets for Unit Pricing Purposes Timing differences Other | 584,621 - | 352,438 | 635,788 |
| Net assets attributable to unitholders as at 30 June | 584,621 | 352,438 | 635,788 |

Significant Changes in State of Affairs

The Funds were constituted on 28 March 2018. The Funds iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF and iShares MSCI Emerging Markets ETF commenced their operations on 14 September 2018, 12 October 2018 and 12 October 2018 respectively.

In the opinion of the directors, there were no other significant changes in the state of affairs of the Funds that occurred during the financial period under review.

Matters Subsequent to the End of the Financial Period

iShares Europe ETF

The Fund announced on 3 July 2019 a final distribution 140.51 cents per unit, which equates to \$15,427,982. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares Global 100 ETF

The Fund announced on 3 July 2019 a final distribution 81.97 cents per unit, which equates to \$18,855,016. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares Global Consumer Staples ETF

The Fund announced on 3 July 2019 a final distribution 74.87 cents per unit, which equates to \$1,819,388. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

Matters Subsequent to the End of the Financial Period (continued)

iShares Global Healthcare ETF

The Fund announced on 3 July 2019 a final distribution 61.69 cents per unit, which equates to \$4,073,166. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares MSCI EAFE ETF

The Fund announced on 3 July 2019 a final distribution 173.27 cents per unit, which equates to \$6,403,140. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares MSCI Emerging Markets ETF

The Fund announced on 3 July 2019 a final distribution 39.96 cents per unit, which equates to \$4,128,424. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

Except as disclosed in the financial statements, no other matter or circumstance has arisen since 30 June 2019 that has significantly affected, or may significantly affect:

- (i) the operations of the Funds in future financial years, or
- (ii) the results of those operations in future financial years, or
- (iii) the state of affairs of the Funds in future financial years.

Likely Developments and Expected Results of Operations

The Funds will continue to be managed in accordance with the investment objectives and guidelines as set out in the governing documents of the Funds and in accordance with the provisions of the Funds' Constitutions.

The results of the Funds' operations will be affected by a number of factors, including the performance of investment markets in which the Funds invest. Investment performance is not guaranteed and future returns may differ from past returns. As investment conditions change over time, past returns should not be used to predict future returns.

Further information on likely developments in the operations of the Funds and the expected results of those operations have not been included in this report because the Responsible Entity believes it would be likely to result in unreasonable prejudice to the Funds.

Indemnification and Insurance of Officers and Auditor

No insurance premiums are paid for out of the assets of the Funds in regards to insurance cover provided to either the officers of the Responsible Entity or the auditor of the Funds. So long as the officers of the Responsible Entity act in accordance with the Funds' Constitutions and the Law, officers remain indemnified out of the assets of the Funds against losses incurred while acting on behalf of the Funds. The auditor of the Funds is in no way indemnified out of the assets of the Funds.

Fees Paid and Interests held in the Funds by the Responsible Entity or its Associates

Fees paid to the Responsible Entity and its associates out of Funds' property during the period are disclosed in Note 11 of the financial statements.

No fees were paid out of Funds' property to the directors of the Responsible Entity during the period. Pursuant to ASIC Corporations (Registered Schemes - Differential Fees) Instrument 2017/40, the Responsible Entity may individually negotiate fees with certain sophisticated or professional investors.

The number of interests in the Funds held by the Responsible Entity or its associates as at the end of the financial period are also disclosed in Note 11 of the financial statements.

Interests in the Funds

The movement in units on issue in the Funds during the period is disclosed in Note 6 of the financial statements.

Value of Assets

The value of the Funds' assets and liabilities is disclosed on the Statements of Financial Position and derived using the basis set out in Note 2 of the financial statements.

Environmental Regulation

The operations of the Funds are not subject to any particular or significant environmental regulations under either Commonwealth, State or Territory law.

Rounding of Amounts

The Funds are registered schemes of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission relating to the "rounding off" of amounts in the directors' report and financial statements. Amounts in the directors' report and financial statements have been rounded to the nearest thousand in accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, unless otherwise indicated.

Additional Disclosure

The Funds have applied the relief available in ASIC Corporations (Disclosing Entities) Instrument 2015/839 issued by the Australian Securities and Investments Commission in the preparation of the report. This class order allows registered schemes with a common responsible entity to include their financial statements in adjacent columns in a single financial report.

The Funds have applied the relief available in ASIC Corporations (Directors' Report Relief) Instrument 2016/188 issued by the Australian Securities and Investments Commission in the preparation of this report. Accordingly, the additional information otherwise required to be included in the directors' report has been disclosed in Notes 5, 6 and 11 of the financial statements.

Auditor's Independence Declaration

A copy of the auditor's independence declaration as required under Section 307C of the *Corporations Act 2001* is set out on page 7.

The financial statements were authorised for issue by the directors on 18 September 2019.

This report is made in accordance with a resolution of the directors.

Director

S Flatman

Sydney

18 September 2019



Deloitte Touche Tohmatsu ABN 74 490 121 060

550 Bourke Street Melbourne VIC 3000 GPO Box 78 Melbourne VIC 3001 Australia

Tel: +61 3 9671 7000 Fax: +61 3 9671 7001 www.deloitte.com.au

18 September 2019

The Board of Directors
BlackRock Investment Management (Australia) Limited
Level 26, 101 Collins Street
Melbourne, VIC 3000

Dear Directors

iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF, and iShares MSCI Emerging Markets ETF (collectively "International 2 Funds")

In accordance with section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of BlackRock Investment Management (Australia) Limited as Responsible Entity of International 2 Funds.

As lead audit partner for the audit of the financial reports of the International 2 Funds for the financial period 29 March 2018 to 30 June 2019, I declare that to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (ii) any applicable code of professional conduct in relation to the audit.

Yours sincerely

DELOITTE TOUCHE TOHMATSU

elth Tolu Tolutu

Neil Brown Partner

Chartered Accountants

Statements of Profit or Loss and Other Comprehensive Income

| | | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|-------|---------------------------------|------------------------------|---|
| | | For the period 29 March 2018 | For the period 29 March 2018 | For the period 29 March 2018 |
| | | to 30 June 2019 | to 30 June 2019 | to 30 June 2019 |
| | Notes | \$'000 | \$'000 | \$'000 |
| Investment income | | | | |
| Interest income | | 6 | 13 | 7 |
| Dividend/distribution income | | 19,334 | 30,251 | 3,051 |
| Net gains/(losses) on financial instruments held at fair value through profit or loss (including FX | | | | |
| gains/(losses)) | 4 | (4,427) | 54,533 | 13,251 |
| Fee rebates from related schemes | 11 | | 4,536 | |
| Total net investment income/(loss) | | 14,913 | 89,333 | 16,309 |
| Expenses | | | | |
| Management fees | 11 | - | 4,540 | - |
| Transaction costs | | 17 | 19 | 15 |
| Custody movement fees | | 2 | 3 | 1 |
| Other expenses | | 1 | | <u> </u> |
| Total operating expenses | | 20 | 4,562 | 16 |
| Profit/(loss) for the period | | 14,893 | 84,771 | 16,293 |
| Other comprehensive income | | | | |
| Total comprehensive income for the period | | 14,893 | 84,771 | 16,293 |

The above Statements of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

Statements of Profit or Loss and Other Comprehensive Income (continued)

| | Notes | iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 \$'000 | iShares MSCI EAFE ETF For the period 29 March 2018 to 30 June 2019 \$'000 | iShares MSCI Emerging Markets ETF For the period 29 March 2018 to 30 June 2019 \$'000 |
|---|-------|---|---|--|
| Investment income | | | | |
| Interest income | | 5 | 4 | 7 |
| Dividend/distribution income | | 9,108 | 9,108 | 11,254 |
| Net gains/(losses) on financial instruments held at fair value through profit or loss (including FX gains/(losses)) | 4 | 13,598 | 17,007 | 58,071 |
| Fee rebates from related schemes | 11 | - | - | - |
| Total net investment income/(loss) | | 22,711 | 26,119 | 69,332 |
| Expenses | | | | |
| Management fees | 11 | - | - | - |
| Transaction costs | | 9 | 3 | 12 |
| Custody movement fees | | 2 | 1 | 2 |
| Other expenses | | 1 | | <u>-</u> |
| Total operating expenses | | 12 | 4 | 14 |
| Profit/(loss) for the period | | 22,699 | 26,115 | 69,318 |
| Other comprehensive income | | | | |
| Total comprehensive income for the period | | 22,699 | 26,115 | 69,318 |

The above Statements of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes

Statements of Financial Position

| Assets Cash and cash equivalents Financial assets held at fair value through profit or loss | Notes 13(b) 7 | iShares Europe ETF As at 30 June 2019 \$'000 15,360 690,813 | iShares Global 100 ETF As at 30 June 2019 \$'000 | iShares Global Consumer Staples ETF As at 30 June 2019 \$'000 |
|---|---------------------|--|---|---|
| Receivables | 8 | 1,049 | 2,193 | 227 |
| Total assets | | 707,222 | 1,621,778 | 184,558 |
| Liabilities Financial liabilities held at fair value through profit or | 0 | | | |
| loss Payables | 9 10 | 2,498 | 2,220 | - 505 |
| | 10 | | | |
| Total liabilities | | 2,500 | 2,223 | <u>505</u> |
| Net assets attributable to unitholders - equity | 6 | 704,722 | 1,619,555 | 184,053 |
| | | | | |
| | | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | | Healthcare ETF As at | EAFE ETF As at | Emerging Markets ETF As at |
| | | Healthcare ETF | EAFE ETF | Emerging Markets ETF |
| | Notes | Healthcare ETF As at 30 June | EAFE ETF As at 30 June | Emerging Markets ETF As at 30 June |
| Assets | Notes | Healthcare ETF As at 30 June 2019 | EAFE ETF As at 30 June 2019 | Emerging Markets ETF As at 30 June 2019 |
| Assets Cash and cash equivalents | Notes 13(b) | Healthcare ETF As at 30 June 2019 | EAFE ETF As at 30 June 2019 | Emerging Markets ETF As at 30 June 2019 |
| Cash and cash equivalents Financial assets held at fair value through profit or loss | 13(b) 7 | Healthcare ETF As at 30 June 2019 \$'000 4,145 580,461 | EAFE ETF As at 30 June 2019 \$'000 | Emerging Markets ETF As at 30 June 2019 \$'000 4,433 631,996 |
| Cash and cash equivalents | 13(b) | Healthcare ETF As at 30 June 2019 \$'000 | EAFE ETF As at 30 June 2019 \$'000 | Emerging Markets ETF As at 30 June 2019 \$'000 |
| Cash and cash equivalents Financial assets held at fair value through profit or loss | 13(b) 7 | Healthcare ETF As at 30 June 2019 \$'000 4,145 580,461 | EAFE ETF As at 30 June 2019 \$'000 6,475 346,131 | Emerging Markets ETF As at 30 June 2019 \$'000 4,433 631,996 |
| Cash and cash equivalents Financial assets held at fair value through profit or loss Receivables | 13(b) 7 | Healthcare ETF As at 30 June 2019 \$'000 4,145 580,461 2,183 | EAFE ETF As at 30 June 2019 \$'000 6,475 346,131 | Emerging Markets ETF As at 30 June 2019 \$'000 4,433 631,996 11,932 |
| Cash and cash equivalents Financial assets held at fair value through profit or loss Receivables Total assets Liabilities Financial liabilities held at fair value through profit or | 13(b) 7 8 | Healthcare ETF As at 30 June 2019 \$'000 4,145 580,461 2,183 586,789 | EAFE ETF As at 30 June 2019 \$'000 6,475 346,131 | Emerging Markets ETF As at 30 June 2019 \$'000 4,433 631,996 11,932 648,361 |
| Cash and cash equivalents Financial assets held at fair value through profit or loss Receivables Total assets Liabilities Financial liabilities held at fair value through profit or loss | 13(b) 7 8 | Healthcare ETF As at 30 June 2019 \$'000 4,145 580,461 2,183 586,789 | EAFE ETF As at 30 June 2019 \$'000 6,475 346,131 2 352,608 | Emerging Markets ETF As at 30 June 2019 \$'000 4,433 631,996 11,932 648,361 |

Statements of Changes in Equity

| Total equity at the beginning of the financial | Notes | | iShares Global 100 ETF For the period 29 March 2018 to 30 June 2019 \$'000 | |
|--|------------------|---|--|--|
| period | | - | - | - |
| Comprehensive income for the period Profit/(loss) for the period Other comprehensive income for the period | | 14,893 | 84,771 | 16,293 |
| Total comprehensive income for the period | | 14,893 | 84,771 | 16,293 |
| Transactions with unitholders Creations Redemptions Units issued upon reinvestment of distributions Distributions paid and payable | 6 6 6 5 | 791,669 (97,876) 48 <u>(4,012</u>) | 1,599,544 (53,277) 214 <u>(11,697</u>) | 178,359 (9,343) 17 (1,273) |
| Total transactions with unitholders | | 689,829 | 1,534,784 | 167,760 |
| Total equity at the end of the financial period | | 704,722 | 1,619,555 | 184,053 |
| | | iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 | iShares MSCI EAFE ETF For the period 29 March 2018 to 30 June 2019 | iShares MSCI Emerging Markets ETF For the period 29 March 2018 to 30 June 2019 |
| | Notes | \$'000 | \$'000 | \$'000 |
| Total equity at the beginning of the financial period | | - | - | - |
| Comprehensive income for the period Profit/(loss) for the period Other comprehensive income for the period | | 22,699 | 26,115 | 69,318 |
| Total comprehensive income for the period | | 22,699 | 26,115 | 69,318 |
| Transactions with unitholders Creations Redemptions Units issued upon reinvestment of distributions Distributions paid and payable | 6 6 6 5 | 597,101 (30,186) 66 (5,059) | 373,070 (43,997) 18 (2,768) | 643,976 (70,320) 108 (7,294) |
| Total transactions with unitholders | | 561,922 | 326,323 | 566,470 |
| | | 301,722 | 320,323 | 300,470 |

Statements of Cash Flows

| | | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|-------|-----------------------|---------------------------------------|---|
| | | | For the period 29 March 2018 to | For the period 29 March 2018 |
| | | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | Notes | \$'000 | \$'000 | \$'000 |
| Cook flows from amounting activities | | - | • | • |
| Cash flows from operating activities Proceeds from sale of financial instruments held at | | | | |
| fair value through profit or loss | | 102,018 | 60,023 | 10,209 |
| Purchase of financial instruments held at fair value | | , | 55,525 | ,, |
| through profit or loss | | (794,541) | (1,605,098) | (178,880) |
| Transaction costs | | (17) | (19) | (15) |
| Interest received | | 4 | 10 | 7 |
| Dividends/distributions received | | 19,334 | 30,251 | 3,051 |
| Fee rebates from related schemes received | | - | 3,473 | - |
| Other income received | | - | - | - |
| Management fees paid | | - | (3,432) | - |
| Operating expenses paid | | <u>(2</u>) | <u>(3</u>) | (1) |
| Net cash inflow/(outflow) from operating activities | 13(a) | (673,204) | (1,514,795) | (165,629) |
| Cash flows from financing activities | | | | |
| Proceeds from creations by unitholders | | 790,622 | 1,598,417 | 178,132 |
| Payments for redemptions by unitholders | | (97,876) | (53,277) | (9,343) |
| Distributions paid | | (3,964) | (11,483) | (1,256) |
| · | | | | |
| Net cash inflow/(outflow) from financing activities | | 688,782 | 1,533,657 | 167,533 |
| Net increase/(decrease) in cash and cash equivalents | | 15,578 | 18,862 | 1,904 |
| Effects of foreign currency exchange rate changes | | , - | , - | , |
| on cash and cash equivalents | | (218) | <u>(197</u>) | |
| Cash and cash equivalents at the end of the period | 13(b) | 15,360 | 18,665 | 1,904 |
| period | 13(0) | 12,230 | , | .,,,,, |
| Non cash financing activities | 13(c) | 48 | 214 | 17 |

Statements of Cash Flows (continued)

| | | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
|---|-------|---------------------------------------|---------------------------------------|---|
| | | For the period 29 March 2018 to | For the period 29 March 2018 to | For the period 29 March 2018 to |
| | | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | Notes | _ | \$'000 | \$'000 |
| Cash flavor from an anation authorities | | • | - | · |
| Cash flows from operating activities | | | | |
| Proceeds from sale of financial instruments held at fair value through profit or loss | | 34,792 | 46,947 | 77,842 |
| Purchase of financial instruments held at fair value | | 31,772 | 10,717 | 77,012 |
| through profit or loss | | (599,342) | (375,761) | (639, 185) |
| Transaction costs | | (9) | (3) | (12) |
| Interest received | | 4 | 2 | 6 |
| Dividends/distributions received | | 9,108 | 9,108 | 11,254 |
| Fee rebates from related schemes received | | - | · - | - |
| Other income received | | - | - | 1 |
| Management fees paid | | - | - | - |
| Operating expenses paid | | <u>(2)</u> | (1) | (2) |
| Net cash inflow/(outflow) from operating activities | 13(a) | (555,449) | (319,708) | (550,096) |
| Cash flows from financing activities | | | | |
| Proceeds from creations by unitholders | | 594,919 | 373,070 | 632,045 |
| Payments for redemptions by unitholders | | (30,186) | (43,997) | (70,320) |
| Distributions paid | | (4,993) | (2,750) | <u>(7,186)</u> |
| · | | (4,775) | (2,730) | (7,100) |
| Net cash inflow/(outflow) from financing activities | | 559,740 | 326,323 | 554,539 |
| Net increase/(decrease) in cash and cash equivalents | | 4,291 | 6,615 | 4,443 |
| Effects of foreign currency exchange rate changes on cash and cash equivalents | | (146) | (140) | (10) |
| Cash and cash equivalents at the end of the period | 13(b) | 4,145 | 6,475 | 4,433 |
| Non cash financing activities | 13(c) | 66 | 18 | 108 |

1 General Information

These financial statements cover iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF and iShares MSCI Emerging Markets ETF (the "Funds") as individual entities. The Funds were constituted on 28 March 2018. The Funds will terminate on the eightieth anniversary of the day the Funds commenced, unless terminated in accordance with the provisions of the Funds' Constitutions.

The Responsible Entity of the Funds is BlackRock Investment Management (Australia) Limited (the "Responsible Entity"). The Responsible Entity's registered office is Level 26, 101 Collins Street, Melbourne, VIC 3000.

The financial statements were authorised for issue by the directors on 18 September 2019. The directors of the Responsible Entity have the power to amend and reissue the financial statements.

The financial statements are presented in the Australian currency.

2 Summary of Significant Accounting Policies

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to the period presented, unless otherwise stated in the following text.

(a) Statement of Compliance and Basis of Preparation

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards and other authoritative pronouncements issued by the Accounting Standards Board and the *Corporations Act 2001* in Australia. The Funds are for-profit unit trusts for the purpose of preparing the financial statements.

The financial statements are prepared on the basis of historical costs, except for financial assets and financial liabilities held at fair value through profit or loss, that are measured at fair value.

The Statements of Financial Position are presented on a liquidity basis. Assets and liabilities are presented in decreasing order of liquidity and are not distinguished between current and non-current. All balances are expected to be recovered or settled within twelve months, except for investments in financial assets at fair value through profit or loss and net assets attributable to unitholders. The amount expected to be recovered or settled within twelve months after the end of each reporting period cannot be reliably determined.

(i) Compliance with International Financial Reporting Standards

The financial statements of the Funds also comply with International Financial Reporting Standards as issued by the International Accounting Standards Board.

(ii) New and amended standards adopted by the Funds

There are no new standards, interpretations or amendments to existing standards that are effective for the first time for the financial period beginning 29 March 2018 that would be expected to have a material impact on the Funds.

(iii) Investment in Subsidiaries

The Fund iShares Global 100 ETF has determined that it meets the definition of an investment entity in accordance with AASB 10 Consolidated Financial Statements. The Fund does not control any of the entities where it has an investment and therefore does not prepare consolidated financial statements. Instead the investments are accounted for at fair value through profit or loss as discussed in Note 2(b).

The Fund receives income in the form of distributions or interest from its investments in unconsolidated subsidiaries, and there are no significant restrictions on the transfer of funds from these entities to the Fund. The Fund has no contractual commitments or current intentions to provide any other financial or other support to its unconsolidated subsidiaries.

(b) Financial Instruments

(i) Classification

The Funds' investments are classified as at fair value through profit or loss. They comprise:

- Derivative financial instruments such as futures, forward foreign exchange contracts, options and swaps. The Funds do not designate any derivatives as hedges in a hedging relationship.
- Investments in listed equities, listed unit trusts, unlisted unit trusts, interest bearing securities and money market securities.

(b) Financial Instruments (continued)

(i) Classification (continued)

Financial assets and financial liabilities held at fair value through profit or loss are those that are managed and their performance evaluated on a fair value basis in accordance with the Funds' documented investment strategy. The Funds' policy is for the Responsible Entity to evaluate the information about these financial instruments on a fair value basis together with other related financial information.

Short sales are classified as financial liabilities at fair value through profit or loss. Short sales are where borrowed securities are sold in anticipation of a decline in the market value of those securities and are made or may be used for various arbitrage transactions.

(ii) Recognition/derecognition

The Funds recognise financial assets and financial liabilities on the date they become party to the contractual agreement (trade date) and recognise changes in fair value of the financial assets or financial liabilities from this date.

Investments are derecognised when the right to receive cash flows from the investments has expired or the Funds have transferred substantially all risks and rewards of ownership.

(iii) Measurement

Financial assets and liabilities held at fair value through profit or loss

Financial assets and liabilities held at fair value through profit or loss are measured initially at fair value excluding any transaction costs that are directly attributable to the acquisition or issue of the financial asset or financial liability. Transaction costs on financial assets and financial liabilities at fair value through profit or loss are expensed immediately. Subsequent to initial recognition, all instruments held at fair value through profit or loss are measured at fair value with changes in their fair value recognised in the Statements of Profit or Loss and Other Comprehensive Income.

Fair value in an active market

The fair value of financial assets and liabilities traded in active markets is based on their quoted market prices at the end of the reporting date without any deduction for estimated future selling costs. The quoted market price used for financial assets and financial liabilities held by the Funds is the last traded market price.

Fair value in an inactive or unquoted market

The fair value of financial assets and liabilities that are not traded in an active market is determined using valuation techniques. These include the use of recent arm's length market transactions, reference to the current fair value of a substantially similar instrument, discounted cash flow techniques, option pricing models or any other valuation technique that provides a reliable estimate of prices obtained in actual market transactions.

Accordingly, there may be a difference between the fair value at initial recognition and amounts determined using a valuation technique. If such a difference exists, the Funds recognise the difference in the Statements of Profit or Loss and Other Comprehensive Income to reflect a change in factors, including time, that market participants would consider in setting a price.

Investments in other unlisted unit trusts are recorded at the net asset value per unit as reported by the Responsible Entity of such funds.

(c) Offsetting Financial Instruments

Financial assets and liabilities are reported on a gross basis in the Statements of Financial Position. Where there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously on default or in the ordinary course of business, the financial assets and liabilities will be offset and reported on a net basis in notes to the financial statements.

(d) Net Assets Attributable to Unitholders

Units are redeemable at the unitholders' option, however, creations and redemptions may be suspended by the Responsible Entity if it is in the best interests of the unitholders.

The units can be put back to the Funds at any time for cash based on the redemption price, which is equal to a proportionate share of the Funds' net asset value attributable to the unitholders.

(d) Net Assets Attributable to Unitholders (continued)

The units are carried at the redemption amount that is payable at balance sheet date if the holder exercises the right to put the unit back to the Funds. This amount represents the expected cash flows on redemption of these units.

Units are classified as equity when they satisfy the following criteria under AASB 132 Financial instruments: Presentation:

- the puttable financial instrument entitles the holder to a pro-rata share of net assets in the event of the Funds' liquidation;
- the puttable financial instrument is in the class of instruments that is subordinate to all other classes of instruments and class features are identical;
- the puttable financial instrument does not include any contractual obligations to deliver cash or another financial asset, or to exchange financial instruments with another entity under potentially unfavorable conditions to the Funds, and it is not a contract settled in the Funds' own equity instruments; and
- the total expected cash flows attributable to the puttable financial instrument over the life are based substantially on the profit or loss.

The Funds' units have been classified as equity as they satisfied all the above criteria.

(e) Cash and Cash Equivalents

Cash and cash equivalents may include cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value, and bank overdrafts. Bank overdrafts and cash will be netted off on the Statements of Financial Position if both are present.

Payments and receipts relating to the purchase and sale of investment securities are classified as cash flows from operating activities as movements in the fair value of these securities represent the Funds' main income generating activity.

(f) Margin Accounts

Margin accounts comprise of cash held for derivative transactions and short sales. The cash is held by the broker and is only available to meet margin calls. Unrestricted margin account balances and restricted margin accounts balances, where the derivative transactions' original maturities are within three months, are classified as cash and cash equivalents. Restricted margin accounts where the derivative transactions' original maturities are not within three months are classified as cash held on collateral.

(g) Investment Income and Expenses

Interest income and expenses are recognised in the Statements of Profit or Loss and Other Comprehensive Income for all interest bearing securities using the effective interest method. Interest income on assets held at fair value through profit or loss is included in the net gains/(losses) on financial instruments. Other changes in fair value for such instruments are recorded in accordance with the policies described in Note 2(b).

The effective interest method is a method of calculating the amortised cost of a financial asset or financial liability and of allocating the interest income or interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments or receipts throughout the expected life of the financial instrument, or a shorter period where appropriate, to the net carrying amount of the financial asset or liability. When calculating the effective interest rate, the Funds estimate cash flows, considering all contractual terms of the financial instrument (for example, prepayment options), but do not consider future credit losses.

The calculation includes all fees and points paid or received between the parties to the contract that are an integral part of the effective interest rate, transaction costs and all other premiums or discounts.

Dividend income is recognised on the ex-dividend date. The Funds may incur withholding tax imposed by certain countries on investment income. Such income is recorded net of withholding tax in the Statements of Profit or Loss and Other Comprehensive Income. If a portion of the foreign withholding taxes is reclaimable, it is recorded as an asset.

Trust distributions are recognised on an entitlements basis.

Dividends declared on securities sold short are recorded as a dividend expense on the ex-dividend date.

(h) Expenses

All expenses, including management fees and performance fees, are recognised in the Statements of Profit or Loss and Other Comprehensive Income on an accruals basis.

(i) Income Tax

Under current legislation, the Funds are not subject to income tax provided the taxable income of the Funds are attributed either by way of cash or reinvestment (i.e. unitholders are presently entitled to the income of the Funds).

The benefit of imputation credits and foreign tax paid are passed on to unitholders.

(i) Distributions to Unitholders

In accordance with the Funds' Constitutions, the Funds attribute their taxable income, and any other amounts determined by the Responsible Entity, to unitholders by cash or reinvestment. Distributions are recognised in the Statements of Changes in Equity as distributions paid and payable.

(k) Increase/Decrease in Net Assets Attributable to Unitholders

Movements in net assets attributable to unitholders are recognised in the Statements of Changes in Equity for the current period ended 30 June 2019.

(I) Foreign Currency Translation

(i) Functional and presentation currency

Items included in the Funds' financial statements are measured using the currency of the primary economic environment in which it operates (the "functional currency"). This is the Australian Dollar, which reflects the currency of the economy in which the Funds compete for funds and is regulated. The Australian Dollar is also the Funds' presentation currency.

(ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the date of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translations at period end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the Statements of Profit or Loss and Other Comprehensive Income.

The Funds do not isolate that portion of gains or losses on securities and derivative financial instruments which is due to changes in foreign exchange rates from that which is due to changes in the market price of securities. Such fluctuations are included with the net gains or losses on financial instruments at fair value through profit or loss.

Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. Translation differences on assets and liabilities carried at fair value are reported as part of the fair value gain or loss.

(m) Receivables

Receivables may include amounts for dividends, interest, trust distributions, amounts due from brokers and creations receivable. Dividends and trust distributions are accrued when the right to receive payment is established. Interest is accrued at the end of the reporting date from the time of the last payment using the effective interest rate method. Amounts due from brokers represent receivables for securities that have been contracted for but not yet delivered by the end of the reporting date. Creations receivable are recorded when the creations are made for units in the Funds with the consideration yet to be received as at the end of the reporting date.

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectible are written off by reducing the carrying amount directly. Using expected credit loss model, an allowance account (provision for impairment of trade receivables) is recorded. Historical experience, financial difficulties of the debtor, probability that the debtor will enter bankruptcy or financial reorganisation, and default or delinquency in payments (more than 30 days overdue) are considered indicators that the trade receivable is impaired. The amount of the impairment allowance is the difference between the asset's carrying amount and the present value of estimated future cash flows, discounted at the original effective interest rate. Cash flows relating to short term receivables are not discounted if the effect of discounting is immaterial.

(m) Receivables (continued)

The amount of the impairment loss is recognised in the Statements of Profit or Loss and Other Comprehensive Income within other expenses. When a trade receivable for which an impairment allowance had been recognised becomes uncollectible in a subsequent period, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are credited against other expenses in the Statements of Profit or Loss and Other Comprehensive Income.

(n) Payables

Payables include liabilities and accrued expenses owing by the Funds and redemptions payable which are unpaid as at the end of the reporting period.

Trades are recorded on trade date, and normally settled within three business days. Purchases of financial instruments that are unsettled at reporting date are included in payables. Redemptions payable are recognised when the unitholder returns their holdings back into the Funds foregoing all rights associated with the units, with the payment yet to be released.

The distribution amount payable to unitholders as at reporting date is recognised separately on the Statements of Financial Position when unitholders are presently entitled to the distributable income under the Funds' Constitutions.

(o) Creations and Redemptions

Creations received for units in the Funds are recorded net of any entry fees payable prior to the issue of units in the Funds. Redemptions from the Funds are recorded gross of any exit fees payable after the cancellation of units redeemed.

Unit redemption prices are determined by reference to the net assets for unit pricing purposes of the Funds, divided by the number of units on issue at or immediately prior to close of business each day. Creations and redemptions of units are processed simultaneously.

(p) Goods and Services Tax (GST)

The GST incurred on the costs of various services provided to the Funds by third parties such as custodial services and investment management fees have been passed onto the Funds. The Funds qualify for Reduced Input Tax Credits (RITC) hence, investment management fees, custodial fees and other expenses have been recognised in the Statements of Profit or Loss and Other Comprehensive Income net of the amount of GST recoverable from the Australian Taxation Office (ATO). Accounts payable and accrued expenses are inclusive of GST. The net amount of GST recoverable from the ATO is included in receivables in the Statements of Financial Position. Cash flows relating to GST are included in the Statements of Cash Flows on a gross basis.

(q) New Accounting Standards and Interpretations

There are no new standards that are not yet effective and that are expected to have a material impact on the Funds in the current or future reporting periods and on foreseeable future transactions.

(r) Use of Estimates and Critical Accounting Judgments

The Funds make estimates and assumptions that affect the reported amounts of assets and liabilities within the next financial year. Estimates are continually evaluated and based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

For the majority of the Funds' financial instruments, quoted market prices are readily available. However, certain financial instruments, for example, over the counter derivatives or unquoted securities are fair valued using valuation techniques. Where valuation techniques (for example, pricing models) are used to determine fair values, they are validated and periodically reviewed by experienced personnel of the Responsible Entity, independent of the area that created them. Models are calibrated by back-testing to actual transactions to ensure that outputs are reliable.

Models use observable data, to the extent practicable. However, areas such as credit risk (both own and counterparty), volatilities and correlations require management to make estimates. Changes in assumptions about these factors could affect the reported fair value of financial instruments.

For certain other financial instruments, including amounts due from/to brokers and payables, the carrying amounts approximate fair value due to the immediate or short term nature of these financial instruments.

(s) Rounding of Amounts

The Funds are registered schemes of a kind referred to in ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, issued by the Australian Securities and Investments Commission relating to the "rounding off" of amounts in the directors' report and financial statements. Amounts in the directors' report and financial statements have been rounded to the nearest thousand in accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, unless otherwise indicated.

(t) Cash Held on Collateral

Cash held on collateral includes restricted margin accounts where the derivative transactions' original maturities are not within three months as well as restricted cash for short sales. Short positions are taken on securities which have relatively poor return expectations. To facilitate settlement, securities are borrowed with collateral requirements. These requirements are satisfied with cash and/or other securities. Cash used to satisfy collateral requirements is disclosed as cash held on collateral on the Statements of Financial Position.

3 Financial Risk Management

The Funds' activities expose them to a variety of financial risks: credit risk, liquidity risk, and market risk (including price risk, currency risk and interest rate risk). The Funds' overall risk management program focuses on ensuring compliance with the Funds' Product Disclosure Statements and seeks to maximise the returns derived for the level of risk to which the Funds are exposed. The Funds may use derivative financial instruments to moderate and create certain risk exposures. Financial risk management is carried out by the Investment Risk Management Working Group (IRMWG) under policies approved by the Board of Directors of the Responsible Entity (the "Board").

The Funds use different methods to measure different types of risk to which they are exposed. These methods include Value at Risk ("VaR") analysis in the case of interest rate, foreign exchange and other price risks and ratings analysis for credit risk. VaR analysis is explained in Note 3(b).

(a) Market Risk

(i) Price Risk

The Funds are exposed to price risk. This arises from investments held by the Funds for which prices in the future are uncertain. They are classified in the Statements of Financial Position as fair value through profit or loss. Where non-monetary financial instruments are denominated in currencies other than the Australian Dollar, the price in the future will also fluctuate because of changes in foreign exchange rates. Note 3(a)(ii) below sets out how this component of price risk is managed and measured. All securities investments present a risk of loss of capital. Except for equities sold short and derivative instruments, the maximum risk resulting from financial instruments is determined by the fair value of the financial instruments. Possible losses from equities sold short can be unlimited.

Market risk is managed and monitored by the Responsible Entity on a portfolio basis, with risks managed through ensuring that investment activities are undertaken in accordance with the Funds' investment model which is reviewed and updated regularly.

The Responsible Entity continuously monitors the Funds' holdings relative to the recommended portfolio, and the exposure of the Funds are monitored to ensure that it remains within designated ranges or asset allocation constraints, taking into account any derivative position being used to manage risks.

In addition, the IRMWG regularly reviews the Funds to ensure the Funds are following the appropriate investment model, their portfolio is in accordance with their stated guidelines and restrictions, and the performance of the Funds remains in expected bounds.

The summarised VaR analysis in Note 3(b) explains how the risk is measured and summarises the potential exposure of the Funds' net assets attributable to unitholders.

(a) Market Risk (continued)

(i) Price Risk (continued)

At the reporting date, the notional principal amounts of derivative financial instruments held by the Funds were as follows:

| | | iShares Euro 30 June \$'000 | 2019 | |
|------------------------------------|---|-------------------------------------|--------------|------------|
| | Notiona Asset | al Principal An Liability | nount Net | Fair Value |
| Forward foreign exchange contracts | 14,772 | (14,774) | (2) | (2) |
| | | iShares Globa 30 June \$'000 | 2019 | |
| | Notiona | al Principal An | nount | Fair Value |
| | Asset | Liability | Net | |
| Forward foreign exchange contracts | 37,029 | (37,032) | (3) | (3) |
| | iShare | s Global Consu 30 June \$'000 | 2019 | es ETF |
| | Notiona | al Principal An | nount | Fair Value |
| | Asset | Liability | Net | |
| Forward foreign exchange contracts | 1,738 | (1,738) | - | - |
| | iShares Global Healthcare ETF 30 June 2019 \$'000 | | | |
| | Notiona | al Principal An | nount | Fair Value |
| | Asset | Liability | Net | |
| Forward foreign exchange contracts | 6,042 | (6,046) | (4) | (4) |
| | | iShares MSCI 30 June \$'000 | 2019 | |
| | Notiona | al Principal An | nount | Fair Value |
| | Asset | Liability | Net | |
| Forward foreign exchange contracts | 6,106 | (6,106) | - | - |
| | iShare | es MSCI Emerg | ing Market | s ETF |
| | | 30 June \$'000 | 2019 | |
| | Notiona | al Principal An | nount | Fair Value |
| | Asset | Liability | Net | |
| Forward foreign exchange contracts | 15,124 | (15,148) | (24) | (24) |

(a) Market Risk (continued)

(ii) Foreign Exchange Risk

The Funds hold monetary and non-monetary assets denominated in currencies other than the Australian Dollar. The foreign exchange risk relating to non-monetary assets and liabilities is a component of price risk. Foreign exchange risk arises as the value of monetary securities denominated in other currencies will fluctuate due to changes in exchange rates.

The summarised VaR analysis in Note 3(b) explains how the risk is measured and summarises the potential exposure of the Funds' net assets attributable to unitholders.

Foreign exchange risk is managed using forward foreign exchange contracts and other derivatives in accordance with Funds guidelines and restrictions. Daily monitoring is undertaken to ensure instruments used and exposures created are consistent with the investment strategy and objectives of the Funds. For accounting purposes, the Funds do not designate any derivatives as hedges in a hedging relationship, and hence these derivative financial instruments are classified as at fair value through profit or loss.

This disclosure for the Funds have not been made on a look through basis for investments held indirectly through underlying funds. The disclosure of foreign exchange risk may not present the true foreign exchange risk profile of the Funds where the underlying fund has a significant exposure to foreign exchange risk.

The following tables summarise the Funds' assets and liabilities, monetary and non-monetary, which are denominated in different currencies:

| | | nares Europe ETF | ırope ETF | | |
|--|---------------------------------------|---------------------------------|-----------------|--|--|
| 30 June 2019 | United States Dollar A\$'000 | Australian Dollar A\$'000 | Total \$'000 | | |
| Assets | | | | | |
| Cash and cash equivalents | 15,250 | 110 | 15,360 | | |
| Financial assets held at fair value through profit or loss* | 690,813 | - | 690,813 | | |
| Receivables | 2 | 1,047 | 1,049 | | |
| Total assets | 706,065 | 1,157 | 707,222 | | |
| Liabilities | | | | | |
| Financial liabilities held at fair value through profit or loss* | - | 2 | 2 | | |
| Payables | 2,497 | 1 | 2,498 | | |
| Total liabilities | 2,497 | 3 | 2,500 | | |
| Net assets attributable to unitholders | 703,568 | 1,154 | 704,722 | | |
| Increase/(decrease) in exposure from currency derivatives | (12,726) | 12,726 | | | |
| Total foreign currency exposure | 690,842 | 13,880 | 704,722 | | |

^{*} Includes listed unit trust holdings and forward foreign exchange contracts which have been classified as Australian Dollar exposure in the above analysis.

(a) Market Risk (continued)

| | iShares Global 100 ETF | | | |
|---|---------------------------------------|---------------------------------|---------------------|--|
| 30 June 2019 | United States Dollar A\$'000 | Australian Dollar A\$'000 | Total \$'000 | |
| Assets | 40.275 | 200 | 40.775 | |
| Cash and cash equivalents Financial assets held at fair value through profit or loss* | 18,365 1,600,920 | 300 | 18,665 1,600,920 | |
| Receivables | 3 | 2,190 | 2,193 | |
| Total assets | 1,619,288 | 2,490 | 1,621,778 | |
| Liabilities | | | | |
| Financial liabilities held at fair value through profit or loss* | 1 | 2 | 3 | |
| Payables | 1,112 | 1,108 | 2,220 | |
| Total liabilities | 1,113 | 1,110 | 2,223 | |
| Net assets attributable to unitholders | 1,618,175 | 1,380 | 1,619,555 | |
| Increase/(decrease) in exposure from currency derivatives | (34,808) | 34,808 | | |
| Total foreign currency exposure | 1,583,367 | 36,188 | 1,619,555 | |

^{*} Includes listed unit trust holdings and forward foreign exchange contracts which have been classified as Australian Dollar exposure in the above analysis.

(a) Market Risk (continued)

| | iShares Global Consumer Staples ETF | | | | |
|---|---------------------------------------|---------------------------------|-----------------|--|--|
| 30 June 2019 | United States Dollar A\$'000 | Australian Dollar A\$'000 | Total \$'000 | | |
| Assets | | | | | |
| Cash and cash equivalents | 1,812 | 92 | 1,904 | | |
| Financial assets held at fair value through profit or loss* | 182,427 | - | 182,427 | | |
| Receivables | | 227 | 227 | | |
| Total assets | <u>184,239</u> | 319 | 184,558 | | |
| Liabilities | | | | | |
| Payables | 505 | | 505 | | |
| Total liabilities | <u>505</u> | | 505 | | |
| Net assets attributable to unitholders | 183,734 | 319 | 184,053 | | |
| Increase/(decrease) in exposure from currency derivatives | (1,288) | 1,288 | | | |
| Total foreign currency exposure | 182,446 | 1,607 | 184,053 | | |

^{*} Includes listed unit trust holdings.

(a) Market Risk (continued)

| | iShares Global Healthcare ETF | | | |
|--|---------------------------------------|---------------------------------|-----------------|--|
| 30 June 2019 | United States Dollar A\$'000 | Australian Dollar A\$'000 | Total \$'000 | |
| Assets | | | | |
| Cash and cash equivalents | 4,050 | 95 | 4,145 | |
| Financial assets held at fair value through profit or loss* | 580,461 | - | 580,461 | |
| Receivables | 1 | 2,182 | 2,183 | |
| Total assets | <u>584,512</u> | 2,277 | 586,789 | |
| Liabilities | | | | |
| Financial liabilities held at fair value through profit or loss* | - | 4 | 4 | |
| Payables | 2,163 | 1 | 2,164 | |
| Total liabilities | 2,163 | 5 | 2,168 | |
| Net assets attributable to unitholders | 582,349 | 2,272 | 584,621 | |
| Increase/(decrease) in exposure from currency derivatives | (1,734) | 1,734 | | |
| Total foreign currency exposure | 580,615 | 4,006 | 584,621 | |

^{*} Includes listed unit trust holdings and forward foreign exchange contracts which have been classified as Australian Dollar exposure in the above analysis.

(a) Market Risk (continued)

| | iShares MSCI EA | | | |
|---|---------------------------------------|---------------------------------|-----------------|--|
| 30 June 2019 | United States Dollar A\$'000 | Australian Dollar A\$'000 | Total \$'000 | |
| Assets | | | | |
| Cash and cash equivalents | 6,294 | 181 | 6,475 | |
| Financial assets held at fair value through profit or loss* | 346,131 | - | 346,131 | |
| Receivables | 1 | 1 | 2 | |
| Total assets | 352,426 | 182 | 352,608 | |
| Liabilities | | | | |
| Payables | 170 | | 170 | |
| Total liabilities | <u>170</u> | | 170 | |
| Net assets attributable to unitholders | 352,256 | 182 | 352,438 | |
| Increase/(decrease) in exposure from currency derivatives | (6,106) | 6,106 | | |
| Total foreign currency exposure | 346,150 | 6,288 | 352,438 | |

^{*} Includes listed unit trust holdings.

(a) Market Risk (continued)

(ii) Foreign Exchange Risk (continued)

| | iShares MSCI Emerging Markets ETF | | | | |
|--|-----------------------------------|----------------------|---------|--|--|
| | United States Dollar | Australian Dollar | Total | | |
| 30 June 2019 | A\$'000 | A\$'000 | \$'000 | | |
| Assets | | | | | |
| Cash and cash equivalents | 4,184 | 249 | 4,433 | | |
| Financial assets held at fair value through profit or loss* | 631,996 | - | 631,996 | | |
| Receivables | 1 | 11,931 | 11,932 | | |
| Total assets | 636,181 | 12,180 | 648,361 | | |
| Liabilities | | | | | |
| Financial liabilities held at fair value through profit or loss* | - | 24 | 24 | | |
| Payables | 12,548 | 1 | 12,549 | | |
| Total liabilities | 12,548 | 25 | 12,573 | | |
| Net assets attributable to unitholders | 623,633 | 12,155 | 635,788 | | |
| Increase/(decrease) in exposure from currency derivatives | 8,378 | (8,378) | | | |
| Total foreign currency exposure | 632,011 | 3,777 | 635,788 | | |

^{*} Includes listed unit trust holdings and forward foreign exchange contracts which have been classified as Australian Dollar exposure in the above analysis.

(iii) Interest Rate Risk

The majority of the Funds' financial assets and liabilities are non-interest bearing. As a result, the Funds are not subject to significant amounts of risk due to fluctuations in the prevailing levels of markets interest rates.

The Funds' exposure to cash flow interest rate risk is limited to their cash and cash equivalents, which are floating rate interest bearing investments. As at 30 June 2019 the total investment in cash accounts of the Funds is set out in the following table:

| | 30 June |
|-------------------------------------|------------|
| | 2019 |
| | \$ |
| iShares Europe ETF | 15,359,607 |
| iShares Global 100 ETF | 18,665,140 |
| iShares Global Consumer Staples ETF | 1,903,917 |
| iShares Global Healthcare ETF | 4,144,726 |
| iShares MSCI EAFE ETF | 6,475,363 |
| iShares MSCI Emerging Markets ETF | 4,432,646 |
| | |

Interest rate risk is mitigated through ensuring activities are transacted in accordance with mandates, overall investment strategy and within approved limits.

(a) Market Risk (continued)

(iii) Interest Rate Risk (continued)

The summarised VaR analysis in Note 3(b) explains how the risk is measured and summarises the potential exposure of the Funds' net assets attributable to unitholders.

The disclosure for the Funds have not been made on a look through basis for investments held indirectly through the underlying fund. The disclosure of interest rate risk may not present the true interest rate risk profile of the Funds where the underlying fund has significant exposure to interest rate risk.

(b) Summarised VaR Analysis

Value at Risk (VaR) is a risk model used to estimate the potential losses that could occur on the Funds' net asset value position due to movements in interest rates, currency and market prices over a given period and for a specified degree of confidence.

The Responsible Entity uses VaR analysis and/or tracking error estimates to measure and manage risk as these are commonly used and understood models, are easily interpreted and are consistent across different types, asset classes and types of funds. For the purpose of these accounts VaR analysis has been presented. The objective in all cases is to estimate potential losses and manage the downside risk.

The following tables summarise the outputs of the VaR model in relation to interest rate, currency and price risk exposures. The total VaR figures are not the sum of individual risk components as this does not include correlations between different risk factors.

The Responsible Entity calculates the VaR relative to the Funds' total value. The analysis implies that the Manager can be 95% confident that the value of the portfolio will not decrease by any more than the figures in the table below over the 5 day period from 30 June.

| | | urope ETF 119 | | | |
|----------------------|---------------------------------------|-------------------------------|--|--|--|
| | \$'000^ | % | | | |
| Total Portfolio Risk | 18,393 | 2.61 | | | |
| | | bal 100 ETF | | | |
| | · · · · · · · · · · · · · · · · · · · | 19 | | | |
| | \$'000^ | % | | | |
| Total Portfolio Risk | 42,270 | 2.61 | | | |
| | | nsumer Staples ETF 119 | | | |
| | \$'000^ | % | | | |
| Total Portfolio Risk | 4,583 | 2.49 | | | |
| | iShares Global | iShares Global Healthcare ETF | | | |
| | 20 | 19 | | | |
| | \$'000^ | % | | | |
| Total Portfolio Risk | 16,428 | 2.81 | | | |
| | iShares MS | CI EAFE ETF | | | |
| | 20 | 19 | | | |
| | \$'000^ | % | | | |
| Total Portfolio Risk | 8,388 | 2.38 | | | |

[^]VaR has been calculated on Net Assets Attributable to Unitholders before rounding.

(b) Summarised VaR Analysis (continued)

| iShares MSCI Emerging Markets ETF | | | | |
|-----------------------------------|------|--|--|--|
| 2019 | | | | |
| \$'000^ | % | | | |
| 18,056 | 2.84 | | | |

Total Portfolio Risk

Detailed information about the models

There are a number of different VaR models used within the Funds Management industry. The Responsible Entity uses one or more of ex-ante and ex-post estimates of portfolio risk and the Monte Carlo simulation model depending on the fund type. Models are calculated using historical data and a covariance matrix where applicable.

The models used by the Responsible Entity have the following features:

- VaR is calculated to a 95 per cent confidence level. VaR at a confidence level identifies the maximum expected loss under that confidence level:
- VaR is calculated for a 5 day holding period. The time horizon of five days is selected to coincide with the period used to analyse the portfolio positions. The risk data is examined in various daily, weekly and monthly forums; and
- The portfolio VaR is not the simple sum of individual asset stand alone VaRs; the correlations among assets in the portfolio are considered.

Although VaR is a valuable risk management tool it should be interpreted, as with all predictive models, with consideration to its assumptions and limitations. The main assumptions and limitations are listed below:

- Some models assume certain financial variables are normally distributed: The normality assumption allows the Responsible Entity to scale portfolio risk estimates to the appropriate confidence levels. The normality assumption is derived from statistical analysis for examining sample populations of observations and the implications of not assuming normality would preclude the use of most statistical tools including mainstream commercial models for risk measurement.
- The use of historical returns and correlations between assets would not take into account future potential events: It is a commonly stated and well recognised limitation that past performance is not a reliable indicator of future performance.
- Model risk, in general terms, is a known limitation that includes: the quality or accuracy of the underlying data, where significant events occur within the data, the changing sensitivity of the Funds' assets to external market factors over time, and appreciating that using only one model may be limiting in itself to obtaining the best understanding of a Funds' risk position.

The Responsible Entity acknowledges these limitations and thus compares ex-ante and ex-post risk estimates to review expectations versus actual outcomes. Should ex-post values differ significantly from ex-ante returns, an assessment of the reasons for this will be made.

The Funds' risk is managed with constant review of both performance and risk numbers by the investment professionals within the business. These reviews consist of:

- Weekly meetings between the global members of Risk & Quantitative Analysis (RQA). These meetings include RQA Australia.
- Monthly meetings between RQA and the Fund Managers.
- Monthly meetings between RQA and the Chief Investment Officer.
- Ad hoc presentations to the Investment Risk Management Working Group (IRMWG) to keep IRMWG abreast of RQA
 processes and latest updates.
- Daily report of performance figures along with a comparison of ex-ante versus ex-post returns sent to RQA London.
- RQA professionals sitting and working closely with the Fund Managers every day.

[^]VaR has been calculated on Net Assets Attributable to Unitholders before rounding.

(c) Credit Risk Exposure

Credit risk is the risk that the counterparty will fail to perform contractual obligations, either in whole or in part, when they fall due

Credit risk primarily arises from the Funds' investment in debt instruments and from trading derivative products. Other credit risk arises from cash and cash equivalents, deposits with banks and other financial institutions, amounts due from brokers and other receivables. None of these assets are impaired nor past due but not impaired.

Market prices generally incorporate credit risk assessments into valuations and risk of loss is implicitly provided for in the carrying value of financial assets and liabilities as they are marked to market.

(i) Interest Bearing Securities

The Funds do not have any direct holding in interest bearing securities. As a result, the Funds may be exposed to other credit risk from cash and cash equivalents, deposits with banks and other financial institutions, amounts due from brokers and other receivables.

(ii) Derivatives

All exchange traded derivatives are executed through brokers, and cleared through a clearing broker and approved by the IRMWG. Over the counter derivative transactions are conducted only with approved counterparties, who meet the applicable specific Funds requirements and where trading documentation is in place.

To minimise credit risk, the Funds only transact with counterparties of investment grade quality (BBB- or above as rated by Standard & Poor's). The Responsible Entity has a process in place to assess the creditworthiness of counterparties and assess that the risk is evenly distributed. Matters arising in relation to counterparties are reviewed regularly by the RQA.

(iii) Settlement of Securities Transactions

All transactions are settled/paid for upon delivery using approved brokers. The risk of default is considered minimal as delivery of securities sold is only made once the broker has received payment. Payment is made on a purchase once the securities have been received by the broker. The trade will fail if either party fails to meet its obligation.

(iv) Other Credit Risk

The exposure to credit risk for cash and cash equivalents, deposits with banks and other financial institutions is considered to be minimal due to the high credit rating of the relevant financial institution. VaR analysis is also used to manage and measure the credit risk of the Funds.

The Funds are not materially exposed to credit risk on other financial assets.

The maximum exposure to credit risk at the reporting date is the carrying amount of cash and cash equivalents and other financial assets. None of these assets are impaired nor past due but not impaired.

The clearing and depository operations for the Funds' security transactions are mainly concentrated with one counterparty, namely JP Morgan Chase Bank NA ("J.P. Morgan"). J.P. Morgan is a member of a major securities exchange, and at 30 June 2019 had a credit rating of A-1. At 30 June 2019, substantially all cash and cash equivalents, balances due from brokers and investments are held in custody by J.P. Morgan.

(d) Liquidity and Cash Flow Risk

Liquidity risk is the risk that the Funds may not be able to generate sufficient cash resources to settle their obligations in full as they fall due or can only do so on terms that are materially disadvantageous. The Statements of Financial Position are presented on a liquidity basis and discussed in Note 2(a).

The Funds are exposed to daily cash redemptions of redeemable units and daily margin calls on derivatives. The liquidity risks associated with the need to satisfy unitholders' requests for redemptions are mitigated by maintaining adequate liquidity to satisfy usual redemption volumes and restricting the investment activities of the Funds to securities that are actively traded and highly liquid. The Funds also maintain continuous monitoring of forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. The Responsible Entity considers and maintains the liquidity of the Funds, in the context of the investment objectives and liquidity requirements of the Funds. Operational procedures are in place to review margin requirements on futures contracts. IRMWG reviews liquidity reports to ensure the Funds have sufficient liquidity to pay client redemptions and meet margin calls as required.

(d) Liquidity and Cash Flow Risk (continued)

The following tables analyse the Funds' financial liabilities and derivative financial instruments (as appropriate) into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts in the tables are contractual undiscounted cash flows.

iShares Europe ETF

| At 30 June 2019 | Less than 1 month \$'000 | 1 - 3 months \$'000 | 3 - 6 months \$'000 | 6 - 12 months \$'000 | 1-3 years \$'000 | 3+ years \$'000 | Total \$'000 |
|---|--------------------------------|------------------------|------------------------|----------------------------|---------------------|--------------------|-----------------|
| Liabilities | - | - | • | - | - | - | - |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 14,772 | - | - | - | - | - | 14,772 |
| Outflows | (14,774) | - | - | - | - | - | (14,774) |
| Payables | (2,498) | <u>-</u> | | | | <u>-</u> | (2,498) |
| Total liabilities | (2,500) | | | | | | (2,500) |
| | | | iShare | s Global 100 | ETF | | |
| At 30 June 2019 | Less than 1 month \$'000 | 1 - 3 months \$'000 | 3 - 6 months \$'000 | 6 - 12 months \$'000 | 1-3 years \$'000 | 3+ years \$'000 | Total \$'000 |
| Liabilities | , | • | • | • | 4 | • | • |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 37,029 | - | - | - | - | - | 37,029 |
| Outflows | (37,032) | - | - | - | - | - | (37,032) |
| Payables | (1,693) | <u>(527</u>) | | | | <u>-</u> | (2,220) |
| Total liabilities | (1,696) | (527) | | | | | (2,223) |
| | | | iShares Globa | ıl Consumer | Staples ETF | | |
| At 30 June 2019 | Less than 1 month \$'000 | 1 - 3 months \$'000 | 3 - 6 months \$'000 | 6 - 12 months \$'000 | 1-3 years \$'000 | 3+ years \$'000 | Total \$'000 |
| Liabilities | | | | | | | |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 1,738 | - | - | - | - | - | 1,738 |
| Outflows | (1,738) | - | - | - | - | - | (1,738) |
| Payables | <u>(505</u>) | | | | | | <u>(505</u>) |
| Total liabilities | (505) | | | | | | <u>(505</u>) |

(d) Liquidity and Cash Flow Risk (continued)

iShares Global Healthcare ETF

| At 30 June 2019 | Less than 1 month \$'000 | 1 - 3 months \$'000 | 3 - 6 months \$'000 | 6 - 12 months \$'000 | 1-3 years \$'000 | 3+ years \$'000 | Total \$'000 |
|---|--------------------------------|------------------------|------------------------|----------------------------|---------------------|--------------------|------------------|
| Liabilities | | | | | | | |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 6,042 | _ | _ | _ | _ | _ | 6,042 |
| Outflows | (6,046) | _ | _ | _ | _ | _ | (6,046) |
| Payables | (2,164) | | - | - | - | _ | (2,164) |
| Total liabilities | (2,168) | | | | | | (2,168) |
| rotat nasmeres | | | | | | | |
| | | | iShare | s MSCI EAFE | ETF | | |
| | Less than | | | 6 - 12 | | | |
| At 30 June 2019 | 1 month | | 3 - 6 months | months | 1-3 years | 3+ years | Total |
| | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 |
| Liabilities | | | | | | | |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 6,106 | _ | _ | _ | _ | _ | 6,106 |
| Outflows | (6,106) | _ | _ | _ | _ | _ | (6,106) |
| Payables | (170) | | _ | _ | _ | _ | (170) |
| - | | | | | | | <u> </u> |
| Total liabilities | (170) | | | | | | (170) |
| | | | iShares MSCI | Emerging M | arkets ETF | | |
| | Less than | | | 6 - 12 | | | |
| At 30 June 2019 | 1 month | 1 - 3 months | 3 - 6 months | months | 1-3 years | 3+ years | Total |
| | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 | \$'000 |
| Liabilities | | | | | | | |
| Financial liabilities held at fair value through profit or loss | | | | | | | |
| Inflows | 15,124 | - | - | - | - | - | 15,124 |
| Outflows | (15,148) | | - | - | - | - | (15,148) |
| Payables | (12,549) | | | | | | <u>(12,549</u>) |
| Total liabilities | (12,573) | | | | | | (12,573) |

(e) Fair Values of Financial Assets and Liabilities

The carrying amounts of the Funds' assets and liabilities at the end of the reporting period approximate their fair values.

Financial assets and liabilities held at fair value through profit or loss are measured initially at fair value. Transaction costs on financial assets and financial liabilities at fair value through profit or loss are expensed immediately. Subsequent to initial recognition, all instruments held at fair value through profit or loss are measured at fair value with changes in their fair value recognised in the Statements of Profit or Loss and Other Comprehensive Income.

The carrying value less impairment provision of other receivables and payables are assumed to approximate their fair value. The fair value of financial liabilities for disclosure purposes is estimated by discounting the future contractual cash flows at the current market interest rate that is available to the Funds for similar financial instruments.

(i) Fair value in an active market

The fair value of financial assets and liabilities traded in active markets is based on their last traded prices at the end of the reporting period without any deduction for estimated future selling costs.

The Funds value their investments in accordance with the accounting policies set out in Note 2(b). For the majority of their investments, the Funds rely on information provided by independent pricing services for the valuation of their investments.

The quoted market price used for financial assets and financial liabilities held by the Funds is the last traded market price. Where the last traded price does not fall within the bid-ask spread, an assessment is performed by the Responsible Entity to determine the appropriate valuation price to use that is most representative of fair value.

A financial instrument is regarded as quoted in an active market if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency and those prices represent actual regularly occurring market transactions on an arm's length basis.

(ii) Fair value in an inactive or unquoted market

The fair value of financial assets and liabilities that are not traded in an active market is determined using valuation techniques. These include the use of recent arm's length market transactions, reference to the current fair value of a substantially similar other instrument, discounted cash flow techniques, option pricing models or any other valuation technique that provides a reliable estimate of prices obtained in actual market transactions.

Where discounted cash flow techniques are used, estimated future cash flows are based on management's best estimates and the discount rate used is a market rate at the end of the reporting period applicable for an instrument with similar terms and conditions.

For other pricing models, inputs are based on market data at the end of the reporting period. Fair values for unquoted equity investments are estimated, if possible, using applicable price/earnings ratios for similar listed companies adjusted to reflect the specific circumstances of the issuer.

The fair value of derivatives that are not exchange traded is estimated at the amount that the Funds would receive or pay to terminate the contract at the end of the reporting period taking into account current market conditions (volatility and appropriate yield curve) and the current creditworthiness of the counterparties. The fair value of a forward foreign exchange contract is determined as a net present value of estimated future cash flows, discounted at appropriate market rates as at the valuation date

Investments in other unlisted unit trusts are recorded at the net asset value per unit as reported by the Responsible Entity of such funds.

(f) Fair Value Hierarchy

The Funds classify fair value measurements using a fair value hierarchy that reflects the subjectivity of the inputs used in making the measurements. The fair value hierarchy has the following levels:

- Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1).
- Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 2).
- Inputs for the asset or liability that are not based on observable market data (that is, unobservable inputs) (level 3).

(f) Fair Value Hierarchy (continued)

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety. For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgment, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgment by the Responsible Entity. The Responsible Entity considers observable data to be that market data that is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market.

The following tables present the Funds' financial assets and liabilities (by class) measured at fair value according to the fair value hierarchy at 30 June 2019.

| | iShares Europe ETF | | | |
|------------------------------------|-------------------------------------|-------------------|-------------------|-----------------|
| | Level 1 | Level 2 | Level 3 | Total |
| As at 30 June 2019 | \$'000 | \$'000 | \$'000 | \$'000 |
| Financial assets | | | | |
| Listed unit trusts | 690,813 | <u>-</u> | <u>-</u> | 690,813 |
| Total | 690,813 | | | 690,813 |
| Financial liabilities | | | | |
| Forward foreign exchange contracts | | 2 | | 2 |
| Total | | 2 | | 2 |
| | | | | |
| | Lavald | iShares Globa | Takal | |
| As at 30 June 2019 | Level 1 \$'000 | Level 2 \$'000 | Level 3 \$'000 | Total \$'000 |
| | \$ 000 | \$ 000 | \$ 000 | \$ 000 |
| Financial assets | 4 (00 000 | | | 1 (00 000 |
| Listed unit trusts | 1,600,920 | - | | 1,600,920 |
| Total | 1,600,920 | | | 1,600,920 |
| Financial liabilities | | | | |
| Forward foreign exchange contracts | - | 3 | - | 3 |
| Total | | 3 | | 3 |
| | | | | |
| | iShares Global Consumer Staples ETF | | | |
| | Level 1 | Level 2 | Level 3 | Total |
| As at 30 June 2019 | \$'000 | \$'000 | \$'000 | \$'000 |
| Financial assets | | | | |
| Listed unit trusts | <u> 182,427</u> | | | 182,427 |
| Total | 182,427 | | | 182,427 |

3 Financial Risk Management (continued)

(f) Fair Value Hierarchy (continued)

| | iShares Global Healthcare ETF | | | |
|------------------------------------|-------------------------------|-----------------|----------------|----------------|
| | Level 1 | Level 2 | Level 3 | Total |
| As at 30 June 2019 | \$'000 | \$'000 | \$'000 | \$'000 |
| Financial assets | | | | |
| Listed unit trusts | <u>580,461</u> | | | <u>580,461</u> |
| Total | 580,461 | | | 580,461 |
| Financial liabilities | | | | |
| Forward foreign exchange contracts | | 4 | | 4 |
| Total | | 4 | | 4 |
| | | iShares MSCI | EAFE ETF | |
| | Level 1 | Level 2 | Level 3 | Total |
| As at 30 June 2019 | \$'000 | \$'000 | \$'000 | \$'000 |
| Financial assets | | | | |
| Listed unit trusts | 346,131 | | | 346,131 |
| Total | 346,131 | | | 346,131 |
| | iSł | nares MSCI Emer | ging Markets E | ΤF |
| | Level 1 | Level 2 | Level 3 | Total |
| As at 30 June 2019 | \$'000 | \$'000 | \$'000 | \$'000 |
| Financial assets | | | | |
| Listed unit trusts | 631,996 | | | 631,996 |
| Total | 631,996 | | | 631,996 |
| Financial liabilities | | | | |
| Forward foreign exchange contracts | | 24 | | 24 |
| Total | | 24 | | 24 |

Investments whose values are based on quoted market prices in active markets, and therefore classified within level 1, include active listed equities, trusts, exchange traded derivatives and money market securities.

Financial instruments that trade in markets that are not considered to be active but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within level 2. These include investment grade corporate bonds, certain listed equities, certain unlisted unit trusts, and over-the-counter derivatives. As level 2 investments include positions that are not traded in active markets and/or are subject to transfer restrictions, valuations may be adjusted to reflect illiquidity and/or non-transferability, which are generally based on available market information.

Investments classified within level 3 have significant unobservable inputs, as they are infrequently traded. As observable prices are not available for these securities, the Responsible Entity has used valuation techniques to derive fair value.

The Funds' assets and liabilities not measured at fair value on a recurring basis (but fair value disclosures are required) at 30 June 2019 have been classified as level 2. The carrying amounts of these assets and liabilities approximate their fair values as at the end of the reporting date.

The Funds did not hold any level 3 instruments during the period 29 March 2018 to 30 June 2019.

There were no transfers between levels for recurring fair value measurements during the period 29 March 2018 to 30 June 2019.

3 Financial Risk Management (continued)

(g) Offsetting Financial Assets and Financial Liabilities

The Funds do not intend to make payments with each counterparty on a net basis therefore the gross amounts below are shown in their Statements of Financial Position. The gross and net positions of financial assets and liabilities are disclosed in the following tables:

| iShares Europe ETF | | | | | |
|-----------------------------|---|---|--|--|----------------------|
| | Gro | ss amounts not offse | t on the Statement of | Financial Position | |
| 30 June 2019 | Gross amount of financial instruments presented in the Statement of Financial Position \$'000 | Amounts subject to master netting arrangements \$'000 | Net amount excluding collateral \$'000 | Cash collateral received/posted \$'000 | Net amount \$'000 |
| Financial liabilities | Ţ 000 | Ţ 000 | \$ 000 | \$ 000 | Ş 000 |
| Derivatives | 2 | | 2 | | 2 |
| Total | 2 | | 2 | | 2 |
| iShares Global 100 ETF | | | | | |
| | Gro | ss amounts not offse | t on the Statement of | Financial Position | |
| | Gross amount of financial instruments presented in the Statement of | Amounts subject to master netting | Net amount | Cash collateral | |
| 30 June 2019 | Financial Position \$'000 | arrangements \$'000 | excluding collateral \$'000 | | Net amount \$'000 |
| Financial liabilities | • | • | • | • | • |
| Derivatives | 3 | | 3 | | 3 |
| Total | 3 | | 3 | | 3 |
| iShares Global Consumer Sta | aples ETF | | | | |
| | Gro | ss amounts not offse | t on the Statement of | Financial Position | |
| | Gross amount of financial instruments presented in the Statement of | Amounts subject to master netting | Net amount | Cash collateral | |
| 30 June 2019 | Financial Position \$'000 | arrangements \$'000 | excluding collateral \$'000 | | Net amount \$'000 |
| Financial liabilities | • | , | • | • | • |
| Derivatives | * | <u> </u> | * | | _* |
| Total | * | | _* | | _* |

^{*} The amount is nil when it is rounded to the nearest thousand dollar.

3 Financial Risk Management (continued)

(g) Offsetting Financial Assets and Financial Liabilities (continued)

| iShares Global Healthcare I | ETF | | | | |
|-----------------------------|---|---|--|--|----------------------|
| | Gro | ss amounts not offse | t on the Statement of | Financial Position | 1 |
| 30 June 2019 | Gross amount of financial instruments presented in the Statement of Financial Position \$'000 | Amounts subject to master netting arrangements \$'000 | Net amount excluding collateral \$'000 | Cash collateral received/posted \$'000 | Net amount \$'000 |
| Financial liabilities | | | | | |
| Derivatives | 4 | | 4 | | 4 |
| Total | 4 | | 4 | | 4 |
| iShares MSCI EAFE ETF | Gros | s amounts not offset | on the Statement of | Financial Position | |
| 30 June 2019 | Gross amount of financial instruments presented in the Statement of Financial Position \$'000 | Amounts subject to master netting | | Cash collateral | Net amount \$'000 |
| Financial liabilities | \$ 000 | \$ 000 | \$ 000 | \$ 000 | \$ 000 |
| Derivatives | | * | _* | | _* |
| Total | | * | _* | | _* |

iShares MSCI Emerging Markets ETF

Gross amounts not offset on the Statement of Financial Position

| 30 June 2019 | financial instruments presented in the Statement of Financial Position \$'000 | Amounts subject to master netting arrangements \$'000 | Net amount excluding collateral \$'000 | Cash collateral received/posted \$'000 | Net amount \$'000 |
|-----------------------|---|---|--|--|----------------------|
| Financial liabilities | | | | | |
| Derivatives | 24 | _ | 24 | _ | 24 |
| Total | 24 | | 24 | | 24 |

^{*} The amount is nil when it is rounded to the nearest thousand dollar.

Gross amount of

Agreements with the derivative counterparties are based on the ISDA Master Agreement. Under the terms of these arrangements, if on any date amounts would otherwise be payable in the same currency and in respect to the same transaction with the counterparty, the obligation may be automatically satisfied and discharged if the party with the larger aggregate amount pays to the other party the excess of the larger aggregate amount over the smaller aggregate amount. In the event of default, the aggregation into a net position owing/receivable to a single counterparty is subject to the terms of the arrangements and the insolvency laws of the relevant jurisdiction of the party in default.

4 Net Gains/(Losses) on Financial Instruments Held at Fair Value Through Profit or Loss

The net gains/(losses) recognised in relation to financial assets and financial liabilities held at fair value through profit or loss:

| | iShares Europe ETF For the period 29 March 2018 to 30 June 2019 \$'000 | • | iShares Global Consumer Staples ETF For the period 29 March 2018 to 30 June 2019 \$'000 |
|---|--|---------------------------------------|--|
| Net gain/(loss) on financial assets and liabilities held at | | | |
| fair value through profit or loss (including FX gains/(losses)) | (4,427) | 54,533 | 13,251 |
| | (4,427) | 54,533 | 13,251 |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | 29 March 2018 to | For the period 29 March 2018 to | 29 March 2018 to |
| | 30 June 2019 \$'000 | 30 June 2019 \$'000 | 30 June 2019 \$'000 |
| Net gain/(loss) on financial assets and liabilities held at fair value through profit or loss (including FX | \$ 000 | \$ 000 | \$ 000 |
| gains/(losses)) | 13,598 | 17,007 | <u>58,071</u> |
| | 13,598 | 17,007 | 58,071 |

5 Distributions to Unitholders

The distributions during the period were as follows:

iShares Europe ETF For the period 29 March 2018 30 June 2019 \$'000 CPU Distributions paid - Quarter 2 33.87 4,012 4,012 iShares Global 100 ETF For the period 29 March 2018 to 30 June 2019 \$'000 CPU Distributions paid - Quarter 2 50.70 11,697 11,697

5 Distributions to Unitholders (continued)

Distributions paid - Quarter 2

Distributions paid - Quarter 2

| iShares Globa Staple: For the 29 Marci to 30 June | s ETF period h 2018 |
|--|---------------------------|
| \$'000 | CPU |
| 1,273 | 86.08 |
| 1,273 | |
| iShares Global H For the 29 March to 30 June | period h 2018 |
| \$'000 | CPU |
| 5,059 | 81.17 |
| 5,059 | |
| iShares MSC For the 29 March to 30 June | period h 2018 |

| Distributions paid - Quarter 2 | | |
|--------------------------------|--|--|
| Distributions paid - Quarter 2 | | |

CPU

74.13

\$'000

2,768

2,768

6 Net Assets Attributable to Unitholders

Under AASB 132 Financial instruments: Presentation, puttable financial instruments meet the definition of a financial liability to be classified as equity where certain strict criteria are met. The Funds shall classify a financial instrument as an equity instrument from the date when the instrument has all the features and meets the conditions.

The Funds meet the criteria set out under AASB 132 and net assets attributable to unitholders is classified as equity.

As stipulated within the Funds' Constitutions, each unit represents a right to an individual share in the Funds and does not extend to a right to the underlying assets of the Funds. There are no separate classes of units and each unit has the same rights attaching to it as all other units of the Funds. Units are created and redeemed at the unitholders' option at prices based on the value of the Funds' net assets at the time of creation/redemption less transaction costs.

Movement in number of units and net assets attributable to unitholders during the period were as follows:

| | iShares Europe ETF | |
|---|--------------------------|-----------------|
| | 30 June 2019 | 30 June 2019 |
| | No.'000 | \$'000 |
| Opening balance | - | - |
| Profit/(loss) for the period | - | 14,893 |
| Creations | 12,611 | 791,669 |
| Redemptions | (1,632) | (97,876) |
| Units issued upon reinvestment of distributions | 1 | 48 |
| Distributions paid and payable | - | (4,012) |
| Closing balance | 10,980 | 704,722 |
| | iShares Globa | al 100 ETF |
| | 30 June 2019 | 30 June 2019 |
| | No.'000 | \$'000 |
| Opening balance | - | - |
| Profit/(loss) for the period | - | 84,771 |
| Creations | 23,807 | 1,599,544 |
| Redemptions | (808) | (53,277) |
| Units issued upon reinvestment of distributions | 4 | 214 |
| Distributions paid and payable | | (11,697) |
| Closing balance | 23,003 | 1,619,555 |
| | iShares Globa Staples | |
| | 30 June 2019 | 30 June 2019 |
| | No.'000 | \$'000 |
| Opening balance | - | - |
| Profit/(loss) for the period | - | 16,293 |
| Creations | 2,561 | 178,359 |
| Redemptions | (132) | (9,343) |
| Units issued upon reinvestment of distributions | 1 | 17 |
| Distributions paid and payable | | (1,273) |
| Closing balance | 2,430 | 184,053 |

6 Net Assets Attributable to Unitholders (continued)

| | iShares Global Healthcare E | |
|---|-----------------------------|-----------------|
| | 30 June | 30 June |
| | 2019 No.'000 | 2019 \$'000 |
| Opening balance | NO. 000 | \$ 000 |
| Profit/(loss) for the period | _ | 22,699 |
| Creations | 6,958 | 597,101 |
| Redemptions | (356) | (30,186) |
| Units issued upon reinvestment of distributions | 1 | 66 |
| Distributions paid and payable | <u>-</u> _ | (5,059) |
| Closing balance | 6,603 | 584,621 |
| | iShares MSCI | EAFE ETF |
| | 30 June | 30 June |
| | 2019 | 2019 |
| | No.'000 | \$'000 |
| Opening balance | - | - |
| Profit/(loss) for the period | - | 26,115 |
| Creations | 4,178 | 373,070 |
| Redemptions | (484) | (43,997) |
| Units issued upon reinvestment of distributions | 1 | 18 |
| Distributions paid and payable | <u>-</u> _ | (2,768) |
| Closing balance | 3,695 | 352,438 |
| | iShares MSCI Markets | |
| | 30 June 2019 | 30 June 2019 |
| | No.'000 | \$'000 |
| Opening balance | - | - |
| Profit/(loss) for the period | - | 69,318 |
| Creations | 11,514 | 643,976 |
| Redemptions | (1,185) | (70,320) |
| Units issued upon reinvestment of distributions | 2 | 108 |
| Distributions paid and payable | | (7,294) |
| Closing balance | 10,331 | 635,788 |

Capital Risk Management

The Funds manage their net assets attributable to unitholders as capital. The amount of net assets attributable to unitholders can change significantly on a daily basis as the Funds are subject to daily creations and redemptions at the discretion of unitholders.

The Funds monitor the level of daily creations and redemptions relative to the liquid assets in the Funds. As of 30 June 2019 the capital of the Funds are represented in the net assets attributable to unitholders table.

In the event of a significant redemption, the Funds' Constitutions allow the delay of payment beyond the usual redemption timeframe but no later than the maximum number of days specified in the Constitution for satisfying redemption requests. Further, in certain circumstances such as disrupted markets, the Constitutions allow payment to be delayed beyond the maximum number of days.

7 Financial Assets Held at Fair Value Through Profit or Loss

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|--|----------------------------------|---------------------------|---|
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Listed unit trusts | 690,813 | 1,600,920 | 182,427 |
| Total financial assets held at fair value through profit or loss | 690,813 | 1,600,920 | 182,427 |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Listed unit trusts | <u>580,461</u> | 346,131 | 631,996 |
| Total financial assets held at fair value through profit or loss | 580,461 | 346,131 | 631,996 |

An overview of the risk exposures relating to financial assets held at fair value through profit or loss is included in Note 3.

8 Receivables

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|--|--------------------------------------|---|
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Creations receivable | 1,047 | 1,127 | 227 |
| Interest receivable | 2 | 3 | - |
| Fee rebates from related schemes receivable | | 1,063 | |
| Total | 1,049 | 2,193 | 227 |
| | | | |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | | | Emerging |
| | Healthcare ETF | EAFE ETF | Emerging Markets ETF |
| | Healthcare ETF As at 30 June | EAFE ETF As at 30 June | Emerging Markets ETF As at 30 June |
| Creations receivable | Healthcare ETF As at 30 June 2019 | EAFE ETF As at 30 June 2019 | Emerging Markets ETF As at 30 June 2019 |
| Creations receivable Interest receivable | Healthcare ETF As at 30 June 2019 \$'000 | EAFE ETF As at 30 June 2019 | Emerging Markets ETF As at 30 June 2019 \$'000 |
| | Healthcare ETF As at 30 June 2019 \$'000 2,182 | EAFE ETF As at 30 June 2019 \$'000 | Emerging Markets ETF As at 30 June 2019 \$'000 11,931 |

There are no past due (not impaired) or allowance for doubtful debts included in the above receivables as at 30 June 2019.

9 Financial Liabilities Held at Fair Value Through Profit or Loss

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|---|----------------------------------|---------------------------|---|
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Forward foreign exchange contracts | 2 | 3 | |
| Total financial liabilities held at fair value through profit or loss | 2 | 3 | |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Forward foreign exchange contracts | 4 | | 24 |
| Total financial liabilities held at fair value through profit or loss | 4 | | 24 |

An overview of the risk exposures relating to financial liabilities held at fair value through profit or loss is included in Note 3.

10 Payables

| | iShares Europe ETF As at 30 June 2019 \$'000 | iShares Global 100 ETF As at 30 June 2019 \$'000 | iShares Global Consumer Staples ETF As at 30 June 2019 \$'000 |
|-------------------------|---|---|---|
| Settlements payable | 2,497 | 1,112 | 505 |
| Management fees payable | - | 1,065 | - |
| Other payables | 1 | 43 | |
| Total | 2,498 | 2,220 | 505 |
| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
| | As at | As at | As at |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$'000 | \$'000 | \$'000 |
| Settlements payable | 2,163 | 170 | 12,548 |
| Management fees payable | - | - | - |
| Other payables | 1 | | 1 |
| Total | 2,164 | 170 | 12,549 |

11 Related Party Transactions

Responsible Entity

The Responsible Entity of the International 2 Funds is BlackRock Investment Management (Australia) Limited (ABN 13 006 165 975, AFSL 230523) whose ultimate holding company is BlackRock, Inc.

BlackRock Investment Management (Australia) Limited is incorporated in Australia and BlackRock, Inc. is incorporated in the United States of America.

Key management personnel

Directors

Key management personnel include persons who were directors of the Responsible Entity at any time during the financial period as follows:

| Director | Date appointed | Date resigned |
|-------------|----------------------------|---------------------|
| M S McCorry | Appointed 2 December 2009 | |
| A Telfer | Appointed 12 December 2013 | |
| S Flatman | Appointed 28 January 2015 | |
| J Collins | Appointed 29 July 2015 | |
| D Rohe | Appointed 27 July 2016 | Resigned 6 May 2019 |

Other key management personnel

No other person had authority and responsibility for planning, directing and controlling the activities of the Funds, directly or indirectly during the financial period.

Key management personnel unitholdings

At 30 June 2019 no key management personnel held units in the Funds.

Key management personnel compensation

Key management personnel are paid by the Responsible Entity. Payments made from the Funds to the Responsible Entity do not include any amounts attributable to the compensation of key management personnel.

Key management personnel loan disclosures

The Funds have not made, guaranteed or secured, directly or indirectly, any loans to the key management personnel or their personally related entities at any time during the reporting period.

Responsible Entity's fees and other transactions

In accordance with the Funds' Constitutions, the Responsible Entity was entitled to receive fees for the provision of services to the Funds.

| | | Fee rebates from related schemes |
|------------------------|-----------|--|
| At 30 June 2019 | \$ | \$ |
| iShares Global 100 ETF | 4,539,873 | 4,536,096 |

11 Related Party Transactions (continued)

Investments

The Funds held investments in the following schemes which were also managed by the Responsible Entity or its related parties:

iShares Europe ETF

| isilales Europe ETF | | | | | | Distributions received/ |
|---|----------------------------|-----------------------------|-----------------------------|----------------------------|---------------------|---------------------------------------|
| 30 June 2019 | Number of units held at | Fair value of units held at | Value of units purchased | Value of units sold during | Interest held at | receivable during the |
| 30 June 2019 | year end | year end | during the year \$ | the year | year end % | year |
| :Charas Furana FTF | Units | \$ | \$ | \$ | % | \$ |
| iShares Europe ETF (U.S.) | 11,000,177 | 690,812,683 | 796,083,539 | 101,046,337 | 27.36 | 19,333,862* |
| iShares Global 100 ETF | | | | | | |
| | | | | | | Distributions received/ |
| | Number of units held at | Fair value of units held at | Value of units purchased | Value of units sold during | Interest held at | received/ receivable during the |
| 30 June 2019 | year end | year end | during the year | the year | year end | year |
| | Units | \$ | \$ | \$ | % | \$ |
| iShares Global 100 ETF (U.S.) | 23,002,569 | 1,600,919,800 | 1,605,159,345 | 58,843,345 | 56.52 | 30,250,769* |
| iShares Global Consumer | Staples ETF | | | | | |
| | • | | | | | Distributions received/ |
| | Number of units held at | Fair value of units held at | Value of units purchased | Value of units sold during | Interest held at | receivable during the |
| 30 June 2019 | year end | year end | during the year | the year | year end | year |
| | Units | \$ | \$ | \$ | % | \$ |
| iShares Global Consumer | 0.400.440 | 100 101 515 | 470 400 505 | 10 100 101 | | 2.054.400# |
| Staples ETF (U.S.) | 2,432,412 | 182,426,567 | 179,682,505 | 10,499,406 | 16.66 | 3,051,102* |
| iShares Global Healthcare | e ETF | | | | | |
| | | | | | | Distributions received/ |
| 20.1 | Number of units held at | Fair value of units held at | Value of units purchased | Value of units sold during | Interest held at | receivable during the |
| 30 June 2019 | year end | year end | during the year | the year | year end | year |
| :01 | Units | \$ | \$ | \$ | % | \$ |
| iShares Global Healthcare ETF (U.S.) | 6,600,846 | 580,460,572 | 601,346,514 | 34,539,465 | 18.46 | 9,107,811* |

^{*} The amount is net of withholdings taxes.

11 Related Party Transactions (continued)

Investments (continued)

iShares MSCI EAFE ETF

| 30 June 2019 | Number of units held at year end Units | Fair value of units held at year end \$ | Value of units purchased during the year \$ | Value of units sold during the year \$ | Interest held at year end % | Distributions received/ receivable during the year \$ |
|---|---|--|--|---|--------------------------------------|--|
| iShares MSCI EAFE ETF | | | | | | |
| (U.S.) | 3,695,383 | 346,131,136 | 375,498,889 | 46,436,789 | 0.40 | 9,108,131* |
| iShares MSCI Emerging M | arkets ETF | | | | | Distributions received/ |
| 30 June 2019 | Number of units held at year end | Fair value of units held at year end | Value of units purchased during the year | Value of units sold during the year | Interest held at year end | receivable during the |
| 30 Julie 2019 | • | • | dui ilig tile yeal | tile year | • | year |
| | Units | \$ | Ş | Ş | % | \$ |
| iShares MSCI Emerging Markets ETF (U.S.) | 10,335,668 | 631,996,457 | 650,872,150 | 76,859,783 | 1.37 | 11,254,262* |

^{*} The amount is net of withholdings taxes.

Related party schemes' unit holdings

The Responsible Entity and its related parties did not hold any units in the Funds as at 30 June 2019.

Other transactions with the Funds

Apart from those details disclosed in this note, no key management personnel have entered into a material contract with the Funds during the financial period and there were no material contracts involving key management personnel's interests subsisting at period end.

12 Remuneration of Auditor

During the period the following fees were paid or payable for services provided by the auditor of the Funds:

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|--|-----------------------|---------------------------|---|
| | | For the period | |
| | | 29 March 2018 | |
| | to | to | to |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$ | \$ | \$ |
| Deloitte Touche Tohmatsu | | | |
| Audit and review of the financial statements | 9,124 | 9,124 | 9,124 |
| Other services | 1,264 | 1,264 | 1,264 |
| Total | 10,388 | 10,388 | 10,388 |

12 Remuneration of Auditor (continued)

| | iShares Global Healthcare ETF | iShares MSCI EAFE ETF | iShares MSCI Emerging Markets ETF |
|--|----------------------------------|------------------------------|---|
| | - | For the period 29 March 2018 | For the period 29 March 2018 |
| | to | to | to |
| | 30 June 2019 | 30 June 2019 | 30 June 2019 |
| | \$ | \$ | \$ |
| Deloitte Touche Tohmatsu | | | |
| Audit and review of the financial statements | 9,124 | 9,124 | 9,124 |
| Other services | 1,264 | 1,264 | 1,264 |
| Total | 10,388 | 10,388 | 10,388 |

Other services relate to the audit of the Funds' compliance plans. The audit fees paid or payable are discharged by the Responsible Entity from the fees earned from the Funds.

13 Reconciliation of Profit/(Loss) to Net Cash Inflow/(Outflow) from Operating Activities

| | iShares Europe ETF | iShares Global 100 ETF | iShares Global Consumer Staples ETF |
|--|---------------------------------------|---------------------------|---|
| | For the period 29 March 2018 to | 29 March 2018 to | For the period 29 March 2018 to |
| | 30 June 2019 \$'000 | 30 June 2019 \$'000 | 30 June 2019 \$'000 |
| (a) Reconciliation of operating profit/(loss) to net cash inflow/(outflow) from operating activities | | | |
| Operating profit/(loss) for the period | 14,893 | 84,771 | 16,293 |
| Net (gains)/losses on financial assets and liabilities held at fair value through profit or loss (including FX (gains)/losses) | 4,427 | (54,533) | (13,251) |
| Proceeds from sale of financial instruments held at fair value through profit or loss | 102,018 | 60,023 | 10,209 |
| Purchases of financial instruments held at fair value through profit or loss | (794,541) | (1,605,098) | (178,880) |
| Net change in receivables and other assets | (2) | (1,066) | - |
| Net change in accounts payables and accrued liabilities | 1 | 1,108 | |
| Net cash inflow/(outflow) from operating activities | (673,204) | (1,514,795) | (165,629) |
| (b) Components of cash and cash equivalents Cash as at the end of the financial period as shown in the Statements of Cash Flows is reconciled to the Statements of Financial Position as follows: | | | |
| Cash | 15,360 | 18,665 | 1,904 |
| Total cash and cash equivalents | 15,360 | 18,665 | 1,904 |
| (c) Non cash financing activities During the period, the following distribution payments were | | | |
| satisfied by the issue of units under the distribution reinvestment plan | 48 | 214 | 17 |

The changes in these amounts each year (as reported in (c) above) represents a non cash financing cost as it is not settled in cash until such time as it becomes attributable (i.e. taxable).

13 Reconciliation of Profit/(Loss) to Net Cash Inflow/(Outflow) from Operating Activities (continued)

| | iShares Global Healthcare ETF For the period 29 March 2018 to 30 June 2019 \$'000 | iShares MSCI EAFE ETF For the period 29 March 2018 to 30 June 2019 \$'000 | iShares MSCI Emerging Markets ETF For the period 29 March 2018 to 30 June 2019 \$'000 |
|--|---|---|--|
| (a) Reconciliation of operating profit/(loss) to net cash inflow/(outflow) from operating activities | | | |
| Operating profit/(loss) for the period | 22,699 | 26,115 | 69,318 |
| Net (gains)/losses on financial assets and liabilities held at fair value through profit or loss (including FX (gains)/losses) | (13,598) | (17,007) | (58,071) |
| Proceeds from sale of financial instruments held at fair value through profit or loss | 34,792 | 46,947 | 77,842 |
| Purchases of financial instruments held at fair value through profit or loss | (599,342) | (375,761) | (639,185) |
| Net change in receivables and other assets | (1) | (2) | (1) |
| Net change in accounts payables and accrued liabilities | 1 | | 1 |
| Net cash inflow/(outflow) from operating activities | (555,449) | (319,708) | (550,096) |
| (b) Components of cash and cash equivalents Cash as at the end of the financial period as shown in the Statements of Cash Flows is reconciled to the Statements of Financial Position as follows: | | | |
| Cash | 4,145 | 6,475 | 4,433 |
| Total cash and cash equivalents | 4,145 | 6,475 | 4,433 |
| (c) Non cash financing activities During the period, the following distribution payments were satisfied by the issue of units under the distribution reinvestment plan | 66 | 18 | 108 |

The changes in these amounts each year (as reported in (c) above) represents a non cash financing cost as it is not settled in cash until such time as it becomes attributable (i.e. taxable).

14 Segment Information

iShares Europe ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the S&P Europe 350 Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the S&P Europe 350 Index. Accordingly, no additional qualitative or quantitative disclosures are required.

iShares Global 100 ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the S&P Global 100 Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the S&P Global 100 Index. Accordingly, no additional qualitative or quantitative disclosures are required.

iShares Global Consumer Staples ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the S&P Global 1200 Consumer Staples Sector Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the S&P Global 1200 Consumer Staples Sector Index. Accordingly, no additional qualitative or quantitative disclosures are required.

iShares Global Healthcare ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the S&P Global 1200 Healthcare Sector Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with S&P Global 1200 Healthcare Sector Index. Accordingly, no additional qualitative or quantitative disclosures are required.

iShares MSCI EAFE ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the MSCI EAFE Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the MSCI EAFE Index. Accordingly, no additional qualitative or quantitative disclosures are required.

iShares MSCI Emerging Markets ETF

The Fund operates solely in the business of providing investors with the performance of the market, before fees and expenses, as represented by the MSCI Emerging Markets Index. The Responsible Entity, which is the chief operating decision maker for the purposes of assessing performance and determining the allocation of resources, ensures that the Fund's holdings and performance are in accordance with the MSCI Emerging Markets Index. Accordingly, no additional qualitative or quantitative disclosures are required.

15 Events Occurring After the Reporting Period

iShares Europe ETF

The Fund announced on 3 July 2019 a final distribution 140.51 cents per unit, which equates to \$15,427,982. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares Global 100 ETF

The Fund announced on 3 July 2019 a final distribution 81.97 cents per unit, which equates to \$18,855,016. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares Global Consumer Staples ETF

The Fund announced on 3 July 2019 a final distribution 74.87 cents per unit, which equates to \$1,819,388. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares Global Healthcare ETF

The Fund announced on 3 July 2019 a final distribution 61.69 cents per unit, which equates to \$4,073,166. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

15 Events Occurring After the Reporting Period (continued)

iShares MSCI EAFE ETF

The Fund announced on 3 July 2019 a final distribution 173.27 cents per unit, which equates to \$6,403,140. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

iShares MSCI Emerging Markets ETF

The Fund announced on 3 July 2019 a final distribution 39.96 cents per unit, which equates to \$4,128,424. The final distribution ex-date was 1 July 2019 and payment was on 11 July 2019.

No other significant events have occurred since the end of the reporting period up to the date of signing the Annual Financial Report which would impact on the financial position of the Funds disclosed in the Statements of Financial Position as at 30 June 2019 or on the results and cash flows of the Funds for the period ended on that date.

16 Contingent Assets, Contingent Liabilities and Commitments

There are no outstanding contingent assets, contingent liabilities or commitments as at 30 June 2019.

Directors' Declaration

In the opinion of the directors of the Responsible Entity:

- (a) the financial statements and notes set out on pages 8 to 50 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
 - (ii) giving a true and fair view of the Funds' financial position as at 30 June 2019 and of their performance, as represented by the results of their operations; changes in equity and its cash flows, for the financial period ended on that date;
- (b) the financial statements also comply with International Financial Reporting Standards as disclosed in Note 2(a); and
- (c) the directors have been given the declarations by the chief executive officer and chief financial officer required by section 295A of the *Corporations Act 2001*.

This declaration is made in accordance with a resolution of the directors.

Director

S Flatman

Sydney

18 September 2019



Deloitte Touche Tohmatsu ABN 74 490 121 060

550 Bourke Street Melbourne VIC 3000 GPO Box 78 Melbourne VIC 3001 Australia

Tel: +61 3 9671 7000 Fax: +61 3 9671 7001 www.deloitte.com.au

Independent Auditor's Report to the Unitholders of International 2 Funds

Opinion

We have audited the financial reports of iShares Europe ETF, iShares Global 100 ETF, iShares Global Consumer Staples ETF, iShares Global Healthcare ETF, iShares MSCI EAFE ETF, and iShares MSCI Emerging Markets ETF (collectively "International 2 Funds" or the "Funds"), which comprises the statements of financial position as at 30 June 2019, the statements of profit or loss and other comprehensive income, the statements of changes in equity and the statements of cash flows for the period then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information, and the directors' declaration.

In our opinion, the accompanying financial reports of the Funds is in accordance with the *Corporations Act 2001*, including:

- (i) giving a true and fair view of the Funds' financial position as at 30 June 2019 and of its performance for the period then ended; and
- (ii) complying with Australian Accounting Standards and the Corporations Regulations 2001.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Funds in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the "Code") that are relevant to our audit of the financial reports in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of Blackrock Investment Management (Australia) Limited (the "Responsible Entity"), would be in the same terms if given to the directors as at the time of this auditor's report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial reports for the current period. These matters were addressed in the context of our audit of the financial reports as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.



Key Audit Matter

How the scope of our audit responded to the Key Audit Matter

Valuation of financial assets and financial liabilities held at fair value through profit or loss

Financial assets and financial liabilities represent the most significant balances in the statement of financial position and are the primary drivers of net asset value and investment performance.

Refer to notes 7 and 9

| Name of the Funds | Financial assets as at 30 June 2019 (in millions) | Financial liabilities as at 30 June 2019 (in millions) |
|---|---|--|
| iShares Europe ETF | 690.81 | - |
| iShares Global 100 ETF | 1,600.92 | - |
| iShares Global Consumer Staples ETF | 182.43 | - |
| iShares Global Healthcare ETF | 580.46 | - |
| iShares MSCI EAFE ETF | 346.13 | - |
| iShares MSCI Emerging Markets ETF | 632.00 | 0.02 |

Our procedures included, but were not limited to:

- Evaluating key controls in place at the administrator in relation to the valuation of financial assets and liabilities, including any exceptions noted;
- Testing on a sample basis, the valuation of listed unit trusts by assessing the last traded market price to external pricing sources; and
- Testing on a sample basis, forward foreign exchange contracts by assessing valuation inputs to observable market data.

We also assessed the appropriateness of the disclosures included in notes 7 and 9 to the financial statements.

Other Information

The directors of the Responsible Entity (the "Directors") are responsible for the other information. The other information comprises the Directors' Report included in the financial reports for the period ended 30 June 2019, but does not include the annual financial reports and our auditor's report thereon.

Our opinion on the financial reports does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial reports, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial reports or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Responsibilities of the Directors for the Financial Reports

The directors are responsible for the preparation of the financial reports that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the financial reports that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial reports, the directors are responsible for assessing the ability of the Funds to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Funds or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibility for the Audit of the Financial Reports

Our objectives are to obtain reasonable assurance about whether the financial reports as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial reports.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial reports, whether due
 to fraud or error, design and perform audit procedures responsive to those risks, and obtain
 audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk
 of not detecting a material misstatement resulting from fraud is higher than for one resulting
 from error, as fraud may involve collusion, forgery, intentional omissions,
 misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Funds' internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Funds' ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial reports or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Funds to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial reports, including the disclosures, and whether the financial reports represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial reports of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Yours faithfully

DELOITTE TOUCHE TOHMATSU

Tole Tolete

Neil Brown Partner

Chartered Accountants